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Viruses, after long periods of time infecting and co-evolving with their hosts have developed 
complex and ingenious ways of manipulating host cell environments to better suit their needs. 
One such example of this is modulation of the cell cycle. One important regulator of the cell 
cycle is the anaphase promoting complex/cyclosome (APC), a ubiquitin ligase. It is important 
in the exit from mitosis, in maintaining the cell in G1 phase and inhibiting the transition into S 
phase until conditions are appropriate. Orf virus expresses a protein called the poxvirus 
anaphase promoting complex/cyclosome regulator (PACR), which interacts with, and 
influences the action of the APC. It is currently suggested that PACR’s inhibition of the APC 
leads the cell to enter a pseudo-S phase like state which increases the levels of cellular 
replicative products for orf virus to use for viral replication. The fact that a PACR deleted 
mutant orf virus (OV PACR KO) shows reduced growth characteristics supports this model, 
but there is no definitive evidence linking PACR’s effects on APC and its role in viral 
replication. Restoration of wild type (WT) levels of growth to the mutant virus when APC is 
inactivated by RNA interference is one means of establishing such a link, and formed the basis 
of this study. 
 
A first step was to identify suitable cells. The limited availability of ovine reagents meant that 
the standard cells used in our studies of orf virus, primary lamb testes (LT cells), were not 
suitable. The growth of WT and OV PACR KO orf virus in LT cells were therefore compared 
to growth in two human cell lines, HeLa and human dermal fibroblasts (HDFs). These studies 
revealed that the impaired growth of OV PACR KO relative to WT seen in LT cells was 
replicated in HDFs. Furthermore, a derivative of OV PACR KO in which a functional PACR 
gene had been restored (OV PACR Restore) showed the same growth characteristics as WT 
orf virus. Intriguingly, all three viruses grew equally well in HeLa cells, perhaps reflecting the 
transformed nature of these cervical carcinoma-derived cells. HDF cells were therefore 
selected to examine the effect of the inactivation of APC following siRNA knockdown (KD) 
of APC11 subunit 11 (APC11). Western blot analysis confirmed effective knock down of 
APC11. APC11 KD cells were infected 72 hours after transfection with WT, OV PACR KO 
and OV PACR Restore virus and viral yields compared to those obtained in normal HDF cells. 
When the growth curves were compared we saw that the WT and Restore viruses had similar 
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growth characteristics in both sets of cells and growth of the OV PACR KO virus was not 
enhanced in the APC11 KD HDF cells. 
 
FACS analysis of propidium iodide stained APC11 KD showed no obvious disruption of the 
cell cycle, including no accumulation of cells in G2/M phase as would be expected upon the 
knock down of APC11. In another functional check on the knock down, western blot analysis 
of thymidine kinase (TK) levels was undertaken. APC directs TK’s proteosomal degradation 
during G1 phase and TK levels rise as cells go through the G1/S transition. Our analysis showed 
a transient increase in TK levels in APC11 KD cells. These results showed that the APC11 KD 
was having the desired effect on APC controlled substrates. However, elevated TK levels 
occurring at 48 post transfection would have been unlikely to benefit viral growth in the 
transfection-infection schedule employed in this study. 
 
An assay of viral β-glucuronidase reporter gene activity was developed as a way of comparing 
virus levels without having to complete lengthy plaque titrations. The assay showed similar 
trends to those seen in the plaque titrations and could be used as a fast method for confirming 
differences in viral load in future studies. 
 
In summary it has been shown that HDF cells are appropriate cells for these studies. Efficient 
knock down of APC11 can be achieved in these cells and resulted in elevated levels of cellular 
TK. Further experiments using a modified schedule will be required to complete the 
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Chapter One: Introduction 
 
1.1 Poxvirus introduction. 
 
Viruses that comprise the family Poxviridae are distinctive due the fact they are obligate 
cytoplasmic replicators made up of enveloped DNA viruses that are the largest of all the animal 
infecting viruses (Buller and Palumbo, 1991). Poxviruses have an extensive host range that 
encompasses both vertebrates and invertebrates, but only 2 have adapted to solely infect 
humans; variola virus and molluscum contagiosum virus (Buller and Palumbo, 1991). Variola 
virus has the distinction of being the only human infecting virus that has been fully eradicated 
outside of stocks kept in government laboratories. Variola virus is the causative agent of 
smallpox and is a highly debilitating and lethal disease that had its last confirmed wild case in 
the 1970’s. Due to the highly virulent nature of variola and other poxviruses a lot of research 
has been conducted, with the prototype species for this research being vaccinia virus, which 
was used as a live vaccine for smallpox (Smith and McFadden, 2002).  
 
The family Poxviridae is divided into 2 subfamilies; Entomopoxvirinae which infect insects, 
and Chordopoxvirinae that infect vertebrates. Chordopoxvirinae is then further subdivided into 
10 genera including Parapoxvirus and Orthopoxvirus which contain orf virus and variola virus, 
respectively. Most poxviruses have primarily adapted to animal reservoirs, with some 
including orf virus and monkey-pox virus able to cause zoonotic infections in humans (Moss, 
2013).  All chordopoxviruses have the same viral morphology, being large, brick shaped DNA 
viruses, they have large, linear double stranded DNA genomes of between 130-360kb 
(McFadden, 2005). The central region of chordopoxvirus genomes (100kb) is highly conserved 
across genera and contains about 90 open reading frames that are responsible for encoding 
homologous proteins with roles in protein processing, virion structure, virion assembly and 
RNA and DNA synthesis (Gubser et al., 2004). The terminal regions of chordopoxvirus 
genomes are variable between genera and encode genes that although not essential for growth 
are important in determining virulence, host range and interaction with/ evasion of the host’s 
immune system (Upton et al., 2003). Examples of these genes include apoptosis inhibitors 
(Westphal et al., 2007), viral Tumour Necrosis Factor receptors (vTNFR) (Johnston and 
McFadden, 2004) and Chemokine Binding Proteins (CBP)(Seet et al., 2003b). The terminal 
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regions of poxviruses also contain inverted repeat sequences and hairpin termini composed of 
AT-rich incompletely bound nucleotides (Moss, 2001).  
 
1.2 Orf Virus 
 
Orf virus is the type species of the parapoxvirus genus, which is differentiated from the other 
poxvirus genera by the fact they have a distinct wrapped virion (WV) structure that resembles 
a ball of wool when viewed using electron microscopy (Spehner et al., 2004). Parapoxviruses 
also have a more ovoid than brick shape and it is because of this distinctive morphology (Tan 
et al., 2009) that Parapoxviruses were first classified as their own genus. Other examples 
include bovine papular stomatitis virus and pseudocowpox virus (Fleming and Mercer, 2007). 
Orf virus has a global distribution with sheep and goats being the animal reservoir and usual 
victims of orf virus (Haig and McInnes, 2002a).  
 
Orf virus is able to cause zoonotic infections in those who come into close and regular contact 
with diseased animals such as farmers and meat workers. Infection occurs when the virus enters 
the body through tears in the epidermal layer of the skin, usually in areas that come into contact 
with the infection such as the hands (McKeever et al., 1988). Infection is normally self-limiting 
in immunocompetent humans and is localised to the replicating keratinocytes where acute 
pustular lesions are formed, these lesions most often resolve after 4-8 weeks with minimal 
scarring to the victim (Groves et al., 1991). In sheep, the lesions cause a highly infectious 
condition called contagious ecthyma that is characterised by lesions around the muzzle and 
nasal area, this can lead to difficulties eating and secondary bacterial infections (Fleming et al., 
2015).  
 
The orf virus genome is the shortest of all Chordopoxvirinae at 138 kbp with an unusually high 
GC content of 66 % (Wittek et al., 1979). The genome is predicted to encode 132 genes (Mercer 
et al., 2006), while the central core encodes the highly conserved poxvirus genes required for 
morphogenesis, structure and basic replication mechanisms (Fleming et al., 2015). As 
mentioned previously the terminal regions of poxviral genomes contain genus or species-
specific factors that decide pathogenesis, host range and virulence. Orf virus is no exception 
with 17 open reading frames (ORFs) that share little to no homology with genes from outside 
the genus Parapoxvirus (Delhon et al., 2004). Despite this orf virus has 111 genes that show 
homology to others seen in poxviruses and contains 88 out of 90 of the core Chordopoxvirus 
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genes (Fleming et al., 2015). Orf virus or its gene products have therapeutic potential for use 
in aiding wound resolution, the treatment of cancer and as a vaccine vector.  
 
1.3 Poxvirus Replication 
 
Our knowledge of poxvirus replication is based largely on studies of vaccinia virus, but this 
pattern of viral replication has been shown to be conserved across other poxviruses. The 
poxviral replication cycle occurs exclusively in the cytoplasm of the infected cell and involves 
two different types of infectious particles; the intracellular mature virion (IMV) and the 
extracellular enveloped virus (EEV) (Schmidt et al., 2012). The IMV is the most abundant form 
and is comprised of the viral core consisting of the dsDNA genome, a lipid bilayer and 2 
proteinaceous lateral bodies (Gomez and Esteban, 2001; McFadden, 2005). The EEV starts out 
as an IMV sheathed in 2 membranes derived from the trans-golgi network. On exit from the 
host cell the IMV acquires a new membrane from the cell plasma membrane and becomes the 
EEV (Locker et al., 2000).  
 
Replication begins with the attachment of the virus to the host cell. The two types of infectious 
particles attach to the host cell through different processes. IMVs attach to the cell through 
binding to cell surface molecules such as glycosaminoglycans (Hsiao et al., 1999). It has also 
been shown in some cases that the IMV is able to use host cell appendages such as filopodia to 
move closer to the cell for attachment (Mercer and Helenius, 2008). There are currently no 
identified cellular attachment factors for the EEVs but it is hypothesised that when the EEV 
comes into contact with the plasma membrane of the host cell the outer layer of the EEV is 
disrupted allowing for the IMV that is now uncovered to attach to the cell (Schmidt et al., 
2012).   
 
Once attached to the host cell the virion can be taken up into the cell through processes such 
as macropinocytosis. This can be aided by the subversion of the host cell actin cytoskeleton by 
phosphatidylserine (PS) on the viral membrane (Mercer and Helenius, 2008). In normal cells 
PS is used as a marker for the macropinocytic uptake of apoptotic waste (Mercer and Helenius, 
2009). Once ingested the viral membrane fuses with the membrane of the vesicle allowing the 
viral core to be released into the cytoplasm where replication can start. Replication begins with 
the viral RNA polymerase and transcription factors beginning the process to allow for the 
expression of the viral early genes under the control of viral promotors (Broyles, 2003). This 
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process begins early after infection before uncoating of the virus particle is complete (Figure 
1). Some poxviral early genes are thought to have roles in the suppression of the host cell 
immune response to the virus and its replication products (Johnston and McFadden, 2003).  
 
Most poxviruses encode one or both of thymidine kinase (TK) and ribonucleotide reductase 
(RR) to increase the pool of free nucleotides available for the synthesis of new DNA (Moss, 
2001). Orf virus is an exception to this as it encodes neither, instead producing a protein called 
poxvirus APC/cyclosome regulator (PACR), which, it is postulated to induce the host cell to 
provide the proteins for the virus. Following on from the transcription of early genes, 
dissolution of the viral core occurs releasing the viral DNA allowing it to be the template for 
DNA synthesis which in the case of vaccinia virus occurs within 2 hours of infection (Moss, 
2013). DNA replication signals the beginning of the transcription of intermediate and late viral 
genes in viral replication factories (Katsafanas and Moss, 2007). Intermediate and late 
transcription unlike early are not just under the control of viral transcription factors as the virus 
has now been able to subvert the host cell machinery to aid in transcription. Concurrent to the 
accumulation of late viral gene products, viral structural proteins are produced and the 
assembly of infectious particles begins (McFadden, 2005). All new virions begin as an IMV 
which ia then trafficked to the golgi body where it undergoes wrapping and becomes an EEV 
as it egresses from the cell. EEVs are normally seen during cell-cell infection whereas the IMV 
is more prevalent in host-host transmission seen after apoptosis of the infected cell (Smith and 














1.4 Modulation of host cell environment. 
 
In many ways the host cell environment is not always suitable for viral replication. To 
overcome this many viruses modulate either the intracellular or extracellular environment of 
the cell. Reasons for doing this include allowing for optimal intracellular conditions for viral 
replication and for escaping or subverting the host’s immune system to the advantage of the 
virus {Finlay, 2006 #96}. Orf virus like all poxviruses encodes a range of proteins with 
differing effects on cell biology (Seet et al., 2003a). Some of these proteins are unique to 
parapoxviruses (Fleming et al., 2015) while others are conserved amongst the broader poxvirus 
family.  
 
Examples of such orf virus proteins include those which are involved in inhibiting the 
signalling pathway of the host cell, Nuclear factor-κB which is an integral part of the innate 
immune system and is involved early on in combating viral infections (Mohamed and 
McFadden, 2009). IL-10 is an anti-inflammatory cytokine, and parapoxviruses including orf 
virus produce an IL-10 like virokine named ORFV-IL-10 (Fleming et al., 1997). This virokine 
has been shown to have immunosuppressive activity equal to that of human IL-10 (Wise et al., 
2007). Mutant viruses in which the ability to produce the ORFV-IL-10 virokine has been 
knocked out have reduced virulence characteristics compared to those seen in WT (Fleming 
and Mercer, 2007). It is hypothesised that these may be contributing factors towards the 
observation that previous orf virus infection offers limited resistance to future infections, 
although the lesions that are present are smaller than the first infection (Haig and McInnes, 
2002b). A live vaccine against orf virus infection has been developed but it only offers a limited 
protection window of between 6-8 months in sheep (Haig and McInnes, 2002a). Vascular 
endothelial growth factors (VEGFs) are important in the proliferation of endothelial cells, 
angiogenesis and increasing the vascular permeability of the skin. Parapoxviruses produce their 
own class of VEGFs called VEGF-E (Wise et al., 1999). VEGF-Es are critical in providing an 
ideal replication environment for the virus and are responsible for the dermal vascularisation 
seen in orf virus lesions and for the healing properties observed and lack of scarring seen at the 
resolution of an orf virus infection (Wise et al., 2012).  
 
Poxviruses are known as master manipulators of the host cell environment, but despite 
influencing nearly every facet of the host cell environment there are very few that have been 
shown to manipulate the cell cycle of infected cells. Orf virus is one such virus that is able to 
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manipulate the cell cycle and it does this through disrupting the Anaphase Promoting 
Complex/Cyclosome (APC) which helps cause a cellular environment more conducive for viral 
replication. PACR is the viral protein responsible for this and is encoded by all the 
parapoxviruses and a small number of other poxviruses (Mo et al., 2009). 
 
1.5 Cell cycle. 
 
The cell cycle is the collective term used to describe the process of the cell acquiring nutrients, 
increasing in size and undergoing replication and is a tightly regulated system. The cell cycle 
is composed of 4 phases; Gap 1 (G1), Synthesis (S), G2, and Mitotic (M) phase. In G1 phase the 
biosynthetic pathways involved in organelle production as well as mRNA and protein synthesis 
increase, this is in response to extracellular signals. Once the requirements for the progression 
of the cell cycle have been met the cell progresses into S phase. It is during this phase that the 
genome of the cell is replicated giving 2 copies of the genome. After genome replication, the 
cell progresses to G2 phase in which the cell again grows larger and synthesises the final 
products needed before division. There is an important checkpoint in the cell cycle at the end 
of G2 phase to stop defective cells from dividing. M phase is where the cell physically divides 
into 2 separate daughter cells. An important cell cycle regulator that is active at both the G1/ S 




The APC is an important cell cycle regulator and integral for cell cycle progression and genetic 
knock outs have been shown to be lethal in all models tested (Thornton and Toczyski, 2003). 
The APC is a multi-subunit RING-E3 ubiquitin ligase that through the ubiquitination of cell 
cycle proteins labels them for degradation by the 26S proteasome (Peters, 2006; Sudakin et al., 
1995) and thus regulates the levels present in the cell. Through the ubiquitination of cell 
substrates, the APC maintains the cell in a stable G1 phase until its inactivation leads to 
progression of the cell into S phase (Mo et al., 2012). The APC is also active, as it is now 
suggested, during M phase and its activity is required for cells to exit mitosis and enter G1 
phase  (Hagting et al., 2002). The human APC is comprised of 19 different subunits with most 
of them being structural, but the APC11 and APC2 subunits make up the catalytic core (Chang 
et al., 2014; Leverson et al., 2000; Skaar and Pagano, 2009). The APC is pictured in Figure 2. 
In late M phase the APC is kept in check by the  spindle assembly checkpoint (SAC) until 
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conditions are appropriate for the binding of the activated Cdc20 allowing the APC to function 
(Acquaviva et al., 2004). For the APC to be able to carry out the functions required of it during 
G1 phase the Cdc20 subunit which is present during M phase needs to be replaced by another 
activator, Cdh1. This switch is mediated by the cyclin B and CDK1, which is responsible for 
phosphorylating Cdh1 to stop it from binding to the APC until required (Hall et al., 2004). 
Cyclin B levels drop when it is time for progression from M phase. This then remains the status 
quo until an accumulation of G1/S phase cyclins causes the phosphorylation of Cdh1 causing 
the inactivation of the APC until reactivated by the SAC (Baker et al., 2007).  
 
The first step of the ubiquitination process involves E1 covalently activating ubiquitin which 
is then able to be transferred to the E2 enzyme. The charged ubiquitin is then transferred from 
E2 to the target substrate, in a process mediated by a ubiquitin ligase (E3) (Scheffner et al., 
1995; Schwartz and Ciechanover, 1999). In the case of APC, the APC11 subunit is responsible 
for recruiting ubiquitin-charged E2 to the E3 complex. This is shown in Figure 2A. Repetition 
of the process leads to the formation of a polyubiquitin chain on the substrate protein. Substrate 
recognition occurs when the D or Ken-box sequences of the substrate are recognised by the 
Doc1 and Cdh1/Cdc20 subunits which then allow for binding and hold the substrate in place 
until after ubiquitination has occurred. The tagged substrates are then released and degraded 
by the 26S proteasome. 
 
It is relatively common for viruses to manipulate the cell cycle. However, surprisingly due to 
the importance of the APC in regulating the cell cycle, only a small number of viruses have 
evolved to target it to disrupt the cell cycle. Some viruses that target the APC include human 
cytomegalovirus, human papillomavirus (HPV), chicken anemia virus, adenoviruses and orf 
virus. Human cytomegalovirus expresses factors able to interrupt APC function through the 
phosphorylation of the Cdh1 subunit, rendering it ineffective at binding substrates (Tran et al., 





Figure 2. APC composition and function.  A) In normal functioning APC the D-box of the 
target substrate is recognised by the Cdh1 or Cdc20 subunit (not shown) which holds it in place. 
E2 binds to APC11 which is in turn bound to APC2. Ubiquitin charged E1 is able to transfer a 
ubiquitin molecule to the E2 associated with APC11 which in turn allows the ubiquitin to be 
added to the target substrate marking them, molecular modelling suggests, for degradation.  B) 
PACR as a homologue of APC11 is able to bind to APC2 in its place. E2 is unable to bind to 
PACR which inhibits the passing of ubiquitin from E2 to the target substrate. This leads to the 





HPV E2 interacts with the Cdh1 and Cdc20 subunits which are important in substrate 
acquisition stopping them from performing as normal. This leads to the activation of cell cycle 
fail safes causing metaphase specific apoptosis of the infected cell (Bellanger et al., 2005). Orf 
virus and other parapoxviruses also disrupt APC function leading, it is believed, to more 
favourable conditions for viral replication. This occurs due to the protein, PACR, which causes 
the cell to go from a stable G1 phase to a pseudo S phase like state and can also cause the 




The PACR protein is encoded by the ORFV014 gene.  PACR is an orf virus RING H2 protein 
and is a structural homologue of the APC11 subunit (Mo et al., 2009). APC11 and PACR share 
a conserved N terminal region which is required to be able to bind with APC2. PACR competes 
with APC11 for binding to APC2 causing impaired function of the APC and dysregulation of 
the cell cycle (Mo et al., 2010) (Figure 2B). PACR, unlike APC11 and other RING-H2 proteins 
does not have ubiquitin ligase activity due to its lack of a conserved Trp residue present in other 
RING-H2 proteins (Katoh et al., 2005; Mo et al., 2009). The Trp is an important residue in the 
RING-H2 finger domain where in APC11 it would interact with the E2 protein (Mo et al., 
2009). The current model of PACR’s function is that when PACR interacts with the APC 
instead of APC11, the APC is no longer able to ubiquitinate the cell cycle regulators required 
for the maintenance of a stable G1 phase causing an abundance of the substrates and the cell 
cycle to become dysregulated so cells in G1 enter a pseudo S phase like state. Although PACR 
has a significant role in the intracellular life cycle of orf virus it is not an essential gene for 
survival of the virus as demonstrated by the creation of a PACR-KO orf virus. However PACR-
KO orf virus has reduced growth characteristics, with the yield of infectious particles being 
about ≈5 % of that seen in the WT and it forms smaller plaques during infection (Mo et al., 
2009). Orf virus infects and replicates in differentiated cells of the epidermis and therefore it 
is postulated that PACR helps induce an environment that is optimal for replication in cells that 
would otherwise be less conducive for replication. 
 
There is a correlation observable in poxviruses that viruses that do not encode PACR encode 
their own enzymes for nucleotide metabolism such as thymidine kinase and ribonucleotide 
reductase, while those that encode PACR do not encode these enzymes. Both thymidine kinase 
and ribonucleotide reductase are substrates of the APC (Mo et al., 2009) so their levels increase 
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during the G1/S phase transition as the control of the cell cycle by APC is lessened. One 
explanation for this correlation is that most poxviruses encode thymidine kinase and 
ribonucleotide reductase to produce the replication components needed to build thousands of 
copies of the viral genome. Parapoxviruses on the other hand encode PACR that induces the 
host cell to produce the building blocks required for viral genome replication. 
 
1.8 RNA interference 
 
Ribonucleic acid interference (RNAi) works through the introduction into cells of dsRNA 
sequences that are complementary to the target genes mRNA in host cells. This dsRNA 
unwinds to form the guide strand and the passenger strand which is degraded. The guide strand 
now known as small interfering ribonucleic acid (siRNA) is then incorporated into the RNA-
induced silencing complex (RISC) (Hammond et al., 2000). This complex is then able to 
recognise the target mRNA and allow it to be cleaved (Fire et al., 1998), stopping translation 
of the target protein from occurring (Baulcombe, 1999; Fire et al., 1998). This activation of the 
RNAi system towards a particular mRNA sequence can then lead to ongoing and systemic 




The main aim of the project was to validate or otherwise, the current model for how PACR 
interacts with the APC and its downstream effects. This model is that there is a direct link 
between PACRs inhibitory effects on the APC and its role in viral replication. This model is 
supported by reduced growth characteristics of the OV PACR KO orf virus compared to wild 
type orf virus. This lead to the hypothesis that experimental inactivation of the APC would 
reduce the difference in growth characteristics between WT and PACR-KO orf virus as 
encoding PACR would confer no advantage to the WT. To achieve this aim RNAi of APC11 
would be carried out before these APC11 knock down cells were infected with virus and growth 
curve analyses carried out. The viral yield would be calculated by using plaque titrations. A 
preliminary aim for the project was to determine which cell type was the most appropriate to 
use for RNAi. Orf virus is primarily cultivated in lamb teste (LT) cells but as they are ovine 
cells there is a reduced pool of reagents that can be used during experiments. Therefore human 
cell types, in this case HeLa or human dermal fibroblast (HDF) cells were tested for suitability 
for ongoing use. 
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The last aim was to see if it was possible to develop an X-Gluc assay to replace the time and 
material consuming plaque titrations currently used to quantify the results of the viral growth 
curves. This is possible due to both the wild type equivalent and OV PACR KO orf viruses 
containing the β-glucuronidase gene thus leading to the production of a blue colour upon the 




Chapter Two: Materials and Methods 
 
2.1 Cell culture  
2.1.1 Cell culture materials 
DMEM: Dulbecco’s Modified Eagle Medium (Sigma; Cat. # D6046). 
FCS: Foetal calf serum (Invitrogen; Cat. # 10437-077). 
Heat treated FCS is held at 56°C for 30 minutes. 
MEM: Minimum Essential Medium (Sigma; Cat. # M0643). 
2x MEM: MEM made up in half the volume of dH2O compared to standard MEM. 
PBS: Phosphate Buffered Saline, 1 PBS tablet dissolved in dH2O then autoclaved. 
PSK (1%): 100 μg/mL penicillin, 100 μg/mL streptomycin, 100 μg/mL kanamycin in 2 mL 
aliquots of dH2O. 
Trypsin (0.25%): 1 PBS tablet, 0.25 g trypsin, EDTA (0.5 M), phenol red indicator (0.4%) in 
dH2O then filter sterilised and stored in -20℃ freezer. 
Trypan Blue (0.2%): 2 g/L of trypan blue in PBS. 
X-Gal: 5-Bromo-4-Chloro-3-Indoyl β-D-Galactopyronoside salt (Glycosynth; Cat. # 70045) 
at 20 mg/mL dissolved in dimethyl formamide. 
X-Gluc: 5-Bromo-4-Chloro-3-Indoyl β-D-Glucuronide cyclohexylammonium salt 
(Glycosynth; Cat. # 70065) at 20 mg/mL dissolved in dimethyl formamide. 
Agar: 2% SeaPlaque agarose in dH2O (Lonza; Cat. # 50100). 
Opti MEM: Reduced serum medium (Sigma; Cat. # 31985-062). 
Propidium Iodide (PI): 1 mg/mL in dH2O 
RNAse: 10 mg/mL in dH2O (Sigma; Cat. # R-4875) 
 
2.1.2 Cell lines.  
Cells used were lamb testis (LT, Primary Sheep, neonate testis), primary human dermal 
fibroblast (HDF) and HeLa cells (Human, cervical cancer). 
 
2.1.3 Culturing. 
2.1.3.1 Media and Incubation.  
HDF and HeLa cells were cultivated in DMEM with the addition of 10% non-heat treated FCS 
for HDF cells and 10% heat treated FCS for HeLa cells. LT cells were cultivated in LT MEM 
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supplemented with 10% heat treated FCS. One aliquot (2 mL) of 1% PSK was added to all 
bottles of media prior to use. All cells were incubated at 37 ℃ in humidified atmosphere with 
5% CO2. 
 
2.1.3.2 Subculturing.  
Once cell confluency in the flask reached 80% the cells were subcultured. The medium was 
removed and cells were washed once with PBS for HeLa cells and twice for LT and HDF cells. 
PBS was then removed and trypsin (1 mL) was added, this trypsin was then removed and new 
trypsin added and incubated at 37 ℃ in a humidified atmosphere with 5% CO2 until the 
monolayer lifted with gentle rocking (approximately 10 minutes). The corresponding medium 
was then added to neutralize the trypsin and the cells were resuspended by pipetting the mixture 
several times. The cell suspension was then distributed as required into cell culture flasks and 
the appropriate medium with 10% final concentration of FCS was added before incubation at 
37 ℃ in a humidified atmosphere with 5% CO2. 
 
2.1.3.3. Counting cells.  
0.1 mL of cell suspension was added to 0.9 mL of Trypan Blue stain and mixed. One drop of 
the stained suspension was placed on both sides of a haemocytometer and a coverslip put on 
top. Cells in the four corners and the centre square were then counted using a light microscope. 
 
2.1.3.4 Freezing.   
To freeze down excess cells for future use a confluent T-175 flask was trypsinized as described 
in 2.1.3.2 and 9 ml of suspension transferred to a 15 mL conical tube. The cells were pelleted 
using a benchtop centrifuge at 1200 rpm for 5 minutes and the medium was removed. The cell 
pellet was resuspended in a mixture of 20% FCS, 70% cell culture medium and 10% of DMSO. 
This suspension was then transferred to a cryovial and put in a -80 ℃ freezer for 24 hours. The 
frozen cryovial was then transferred to liquid nitrogen for long term storage. 
 
2.1.3.5 Thawing.   
To revive cells frozen as described in 2.1.3.4 a cryovial was removed from liquid nitrogen 
storage and thawed in a 37 ℃ water bath. The cell suspension was then transferred to a T-25 
flask and 4 mL of the appropriate medium with 10% FCS added and incubated at 37 ℃ in a 




2.1.4 Cell cycle synchronisation.  
Cells were synchronised at the G2/M phase transition through treatment with Nocadozole. HDF 
cells were seeded at 9am in 6 well plates and incubated at 37 ℃ in humidified atmosphere with 
5% CO2. At 5pm Nocadozole at 50 μg/mL was added to the media. Cells were then incubated 
overnight. In the morning the treated cells were harvested, the cells were released from the 
bottom of the well by gently tapping the plate. The media was then transferred to a 15 mL 
Falcon tube and centrifuged at 1200 rpm for 5 minutes. The supernatant was then removed and 
the cell pellet resuspended in 5 mL of PBS and centrifuged again. The cells were then fixed as 
described in 2.1.5. 
 
2.1.5 Ethanol fixing of cells.  
Cells from individual wells in 6 well plates were harvested via scraping and the cell suspension 
was transferred to a 15 mL Falcon tube. The cells were then spun at 1200 rpm for 5 minutes, 
the supernatant was removed and the cells resuspended slowly in 1 mL of PBS. 3 mL of ice 
cold 70 % ethanol was then added, the tubes were then incubated overnight at 4℃. 
 
2.1.6 Fluorescence-activated cell sorting (FACS).  
Ethanol fixed cells described in 2.1.5 were spun at 1600 rpm for 5 minutes, the supernatant 
was then discarded and the cells resuspended in 5 mL of PBS. The cells were then spun again 
at 1600 rpm for 5 minutes and the supernatant discarded. The cells were then resuspended in 
470 μL PBS, 25 μL Propidium iodide stain and 5 μL of RNAse and incubated for 30 minutes 
at 37 ℃ in humidified atmosphere with 5% CO2. The mixture was then transferred to a FACS 
tube. Cells were run through the flow cytometer (BD LSRFortessa) using the FL-2 channel and 
the cellular DNA content of 5000 cells determined. Cell aggregations and doublets were 
eliminated through appropriate gating in the BD FACSDiva software. The data was analysed 
by the MODFIT software program (Verity Software). 
 
2.2 Virus Methods 
2.2.1 Virus infections 
2.2.1.1 Virus strains.  
Three strains of orf virus were used, all derivatives of the orf virus NZ2 strain. OV 893/OV 
890 are recombinant orf viruses carrying the Escherichia coli β-glucuronidase gene directed 
by the orf virus PH5 promotor (Tan et al., 2009), thus allowing plaques to be stained with X-
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Gluc. This expression cassette has been inserted into the intergenic region between the orf virus 
genes 128 and 129. Unpublished work has shown that OV OV 893/OV 890 have growth 
kinetics that are indistinguishable from the NZ2 wild type orf virus (Mercer). OV OV PACR 
KO and OV OV PACR Restore have previously been described in detail (Mo et al., 2009). 
Briefly, OV OV PACR KO is a recombinant orf virus, strain NZ2 for which sequences that 
encode PACR were deleted and replaced by an expression cassette containing E. coli xanthine 
guanine phosphoribosyl transferase gene directed by the P7.5 poxvirus promoter and the E. 
coli β-glucuronidase gene directed by the PH5 promotor allowing plaques to be stained with 
X-Gluc. OV OV PACR Restore is derived from OV OV PACR KO by the reinsertion of the 
full coding region of PACR into its native site in the genome under the control of its natural 
orf virus promotor, and replacing the reporter cassette with β-galactosidase under the control 
of the late promoter, PF1. 
 
2.2.1.2 Orf virus infections.  
Frozen virus preparations in 15 mL conical tubes were thawed in the 37 ℃ water bath and then 
sonicated in a W385 sonicator for 1 minute at 20% power for each tube. The sonicated virus 
preparations were then diluted to the required concentrations by adding virus to the appropriate 
volume of serum free medium. A 200 μL volume of the mixture was added to each well in a 6 
well plate pre-seeded with the appropriate cells that have undergone a PBS wash. The infected 
6 well plates were then incubated in the virus incubator at 37 ℃ and 5% CO2 for 1 hour, with 
gentle rocking of the plate every 15 minutes to stop the cell monolayer from drying out and 
ensuring an even coverage of virus across the monolayer. After incubation, the inoculum was 
removed and a PBS wash performed twice followed by the addition of 1.5 mL of appropriate 
medium with 2% FCS to the monolayer. The 6 well plates were then incubated at 37 ℃ in a 
humidified atmosphere with 5% CO2 for the required time. 
 
2.2.1.3 Harvesting infected cells.  
The infected cell monolayer was lifted from the bottom of the well by scraping the tip of a 
plunger from a 1 mL syringe along the bottom. The resulting cell suspension was then 
transferred to 15 ml falcon tubes and stored at -80 ℃ until needed. 
 
2.2.1.4 Plaque titration.  
To calculate viral titres plaque titrations were performed. Virus samples were prepared as 
described in 2.2.1.2 and 10-fold serial dilutions were performed to the required dilution. These 
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dilution series were used to infect 6 well plates of LT cells as in 2.2.1.2. After infection a 1:1 
mixture of 2% molten agarose and 2x LT MEM with 2% FCS was added on top of the 
monolayer and allowed to set at room temperature before incubation at 37℃ in a humidified 
atmosphere with 5% CO2 for 5 days. 
 
2.2.2 Staining.  
To allow for easier counting of plaques, staining was performed with a mixture of X-Gal or X-
Gluc and Neutral Red. 1.5 mL of a 1:1 mixture of PBS + stain and 2% molten agarose was 
distributed on top of the agar layer from 2.2.1.4. When using X-Gal to stain plaques, 35 μL 
was added and for X-Gluc 15 μL per well of a 6 well plate when needed. Neutral Red was 
added to make up a final concentration of 0.015%. 
 
2.2.3 X-Gluc assay.  
100 μL of the PACR-KO and WT PACR orf virus growth curve samples for each time point 
were used to make a doubling dilution with the corresponding medium as diluent down to the 
appropriate dilution. Samples were lysed as described in 2.2.1.2. 100μL of each dilution was 
then pipetted into a flat bottomed 96 well plate. 100μL of X-Gluc was then added to 900μL of 
PBS and 10μL of the resulting mix was added to each well. Plates were incubated at 37℃ in a 
humidified atmosphere with 5% CO2. The plate was read using a Biorad Model 680 microplate 
reader at 570nm and Microplate manger 5.2 software.  
 
2.3 RNA Materials and Methods 
2.3.1 RNAi Materials 
siRNAs: See Table 1. All siRNA’s used were part of the ON-TARGETplus SMARTpool 
siRNA by Dharmacon (Cat. # L-006992-00-0005). 
GenePharma negative control siRNA (Cat. # A06001) 
Lipofectamine RNAimax: (Invitrogen; Cat. # 13778-075). 
 
2.3.2 RNAi transfection.  
HDF cells were seeded at 60% confluency in 6 well plates 24 hours before transfection. HDF 
cells were transfected with both targeting and control siRNAs following the manufacturers 
transfection protocols. The required amount of siRNA was added to 100 μL of OptiMEM in a 
microfuge tube. In a separate microfuge tube 4μL of Lipofectamine RNAimax was added to 
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100 μL of OptiMEM. Both tubes were then incubated for 5 minutes at room temperature, after 
which the Lipofectamine/OptiMEM mixture was added to the siRNA mixture to make the 
transfection complex and left at room temperature for 30 minutes. During this incubation the 
cells underwent a PBS wash and 800 μL of OptiMEM was added to each well. After incubation 
the transfection complex was added to the OptiMEM covering the cells and was incubated for 
12 hours at 37 ℃ in a humidified atmosphere with 5% CO2. After 12 hours the OptiMEM 
medium was removed and a PBS wash undertaken, 1.5 mL of DMEM and 2% FCS was then 
added to the cells and incubation resumed. Once the cells had been incubated for 72 hours they 
were harvested using the same method as 2.2.1.3. If virus infection of siRNA transfected cells 
was required this was carried out after 72 hours in leu of harvesting. 
 
2.4 Protein Materials and Methods 
2.4.1 Protein Materials 
Running buffer: 3.03 g/L Tris base, 14.4 g/L glycine, 0.1% SDS. 
Transfer buffer: 3.03 g/L Tris base, 14.4 g/L glycine, 0.1% SDS, 20% Methanol. 
Gel: Bolt precast 12 well 4-12% gradient Bis-Tris Plus SDS-PAGE gel (Thermofisher; Cat. # 
NW04122). 
Ladder: SeeBluePlus 2 (Invitrogen; Cat. # CC5925).  
TBS: 20nM Tris-Cl pH 7.6, 0.5 mM NaCl. 
Lysis buffer: 0.02% azide, 150 nM NaCl, 0.25% CHAPS, 0.5% Triton X100, 100 mM Tris 
pH 8.0. 
Protease inhibitor: Roche complete TM Protease inhibitors.  
Bolt reducing agent: (Life Technologies; Cat. # B0009). 
Bolt sample buffer: (Life Technologies; Cat. # B0007). 
Nitrocellulose membrane: Hybond-C (Amersham Bioscience, Cat. # 10600016). 
Detection reagent: ECL Prime Western Blot detection reagent (GE Healthcare; Cat. # 
RPN2236). 
Antibodies: See Table 2.  
 
2.4.2 Cell lysates.  
HDF cells were seeded into 6 well plates as described in 2.1.3 and incubated overnight at 37 
℃ in a humidified atmosphere with 5% CO2 for 24 hours. If transfection was required it was 
carried out as described in 2.3.2. The cells were detached from the well as described in 2.2.1.3 
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and transferred into a microfuge tube and centrifuged at 450 rpm for 5 minutes. The cells were 
then resuspended in 50 mL of PBS and counted as in 2.1.3.3, then spun again and resuspended 
in 1 mL PBS and spun again. The resulting pellet was resuspended at 1x108 cells/mL in lysis 
buffer and protease inhibitors and incubated on ice for 30 minutes. After incubation the 
suspension was centrifuged at 4 ℃ for 10 minutes at 1400 rpm. The pellet was then discarded 
and the supernatant stored at -80 ℃. 
 
2.4.3 Polyacrylamide Gel Electrophoresis (PAGE). 
 To prepare the samples for use in PAGE, cell suspensions were combined with reducing agent 
and Bolt sample buffer. Lysis buffer was added to make all volumes the same. The samples 
were boiled for 5 minutes and placed in ice. A precast PAGE gel was prepared as per the 
manufacturer’s instructions and placed into the Bolt tank. Running buffer was added to the tank 
to the required level. SeeBlue Plus2 protein standard ladder (4 μL) was added into the first well 
to aid in the identification of proteins. A portion of sample was added into the empty wells of 
the gel. Gel electrophoresis was done at 100 V for 90 minutes. 
 
2.4.4 Western Blotting.  
Nitrocellulose membrane and 2 pieces of filter paper were cut to the same size as the gel 
section. 2 foam pads were soaked in transfer buffer and the air bubbles were rolled out of them. 
One soaked foam pad was then put onto the lower half of the transfer module, followed by a 
pre-soaked piece of filter paper. The plastic covering on top of the gel was removed and excess 
gel cut off, the gel was separated from the bottom of the casing and placed on top of the pre-
soaked sponge pad and filter paper. The nitrocellulose membrane was placed on top of the gel 
followed by pre-soaked filter paper and foam pad. The lid of the transfer module was connected 
to the bottom and the module was placed into the Bolt tank. The tank was then filled with 
transfer buffer. Protein transfer was performed at 10 V for one hour. After transfer, the 
membrane was put into a 50 mL Falcon tube and blocked for 2 hours with rolling using 5 mL 
of 1% BSA in TBS. After blocking 5 μL of primary anti- APC11 antibody was added to a 5 
mL solution of 1% BSA/0.05% Tween20/TBS. The tube was then incubated overnight with 
rolling at 4 ℃. The membrane was then washed 3 times with 5 mL of 0.1% Tween20/TBS for 
10 minutes with rolling at room temperature. Secondary antibody (5 μL) was added to the 
membrane in 5 mL of % BSA/0.05% Tween20/TBS followed by incubation for 1 hour at room 













Name Sequence (5’ to 3’) Primer length (bp) 
siRNA J-006992-06, ANAPC11 GGCCAACGAUGAGAACUGU 19 
siRNA J-006992-07, ANAPC11 AAGAUUAAGUGCUGGAACG 19 
siRNA J-006992-08, ANAPC11 UCUGCAGGAUGGCAUUUAA 19 
siRNA J-006992-09, ANAPC11 GUCAAACCCUGAGUCAUGA 19 
Negative Control siRNA UUCUCCGAACGUGUCACGUTT 21 
Antibody Type Supplier & CAT.   # Dilution 
Primary Anti-APC11 Rabbit/polyclonal Abcam; ab154546 1/1000 




Thymidine Kinase 1 
Goat/polyclonal Abcam; ab57757 1/2000 
Secondary Anti-
Rabbit IgG HRP 
Goat/polyclonal DAKO; P0448 1/1000 
Secondary Anti-Goat 
IgG HRP 




After washing the membrane was removed from the Falcon tube and put on top of a piece of 
plastic on a developing plate. 0.5 mL of a 1:1 mixture of detection reagents was then added on 
top and after 1 minute the membrane was imaged using the Odyssey Fc machine for 30 seconds 
at 600nm, 30 seconds at 700nm and then 10 minutes using chemiluminescence. After imaging 
for APC11 the membrane was washed with TBS and then blocked again as described above. 
Primary anti-actin antibody was then added to a 5 mL solution of 1% BSA/0.05% 
Tween20/TBS and incubated for 1 hour at room temperature with rolling. The membrane was 
then washed 3 times with 5 mL of 0.1% Tween20/TBS for 10 minutes with rolling at room 
temperature. Secondary antibody was then added to a 5 mL solution of 1% BSA/0.05% 
Tween20/TBS and incubated at room temperature for 1 hour with rolling. The membrane was 
then washed and imaged as described above. Band intensities were analysed using Image J 
software.  
 
2.5 Statistical Methods 
 
Statistical analyses were performed using an unpaired, non-parametric Mann-Whitney U test 
carried with Prism software. Results were deemed significant if P < 0.05. This test was chosen 
because the number of replicates conducted were too few to assume a normal distribution 




Chapter Three: Results 
 
 
3.1 Analysis of viral growth in LT cells 
 
Previous work has shown that WT and OV PACR KO ORFV have differing growth 
characteristics in LT cells (Mo et al., 2009). This observation has not been as extensively tested 
in HDF and HeLa cells but, due to the limitations involved with using ovine cells human cells 
were tested for use in ongoing experiments. The results of the growth curves in the LT cells 
were used as a comparative benchmark to identify which of the cell types was the best choice 
to use in subsequent experiments. Multi step growth curves were undertaken to examine if the 
differences seen between the 3 viral strains in LT cells were also present in HDF and HeLa 
cells. An initial growth curve experiment was conducted to confirm the previously observed 
reduced growth of OV PACR KO orf virus compared to WT orf virus.  
 
In this experiment OV OV 893 was used as a surrogate of WT orf virus. OVOV 893 has been 
shown to have the same growth characteristics as WT orf virus (Mercer). OV PACR KO orf 
virus was created through the deletion of the PACR gene and replacing it with an expression 
cassette containing the E. coli β-glucuronidase gene. The Restore virus was created from OV 
PACR KO by reinserting the PACR gene into its native site.  LT cells were used to seed 6 well 
plates at a concentration of 4x105 cells/well, which after an overnight incubation reach a density 
of 8x105 cells/well. Using this value and the multiplicity of infection (MOI) of 0.01, the amount 
of each virus sample required was calculated. This leads to a pfu/well of 8x103 in 200 μL of 
medium. 
 
For each multi-step growth curve 2 time points were harvested in duplicate resulting in 4 wells 
needing to be set up at the start of the experiment for each virus strain. Time 0 (T0) samples 
were harvested at the conclusion of the infection procedure outlined in 2.2.1.3 and after 1.5 mL 
of medium was added to each well. Time 5 (T5) samples were harvested 120 hours post 
infection. The replication time for orf virus is approximately 24 hours so harvesting after 5 
days allows for multiple rounds of viral replication and for all cells to be infected (Mercer). 
Each time point was harvested as described in 2.2.1.3 was used to make a dilution series for 
plaque titration using LT cells. The dilution series were 10-1, 10-2 and 10-3 for all 3 strains at 
23 
 
T0 and 10-4, 10-5 and 10-6 for OV 893 and Restore and 10-3, 10-4 and 10-5 for OV PACR KO at 
T5. The dilution series were used to infect duplicate wells and incubated at 37 ℃ in a 
humidified atmosphere with 5% CO2 for 5 days. Plaques were stained after 5 days to allow for 
easier counting as described in 2.2.2. 
 
The results of two independent growth experiments are shown in Figure 3. For LT growth 
curve 1, plaques for the T0 samples were counted in the 10-1 wells for all virus strains. OV 893 
had 11 and 6 plaques in the 2 wells counted, this lead to a viral titre of 4.25x102 pfu/mL. Restore 
had 18 and 20 plaques in the counted wells giving a viral titre of 9.50x102 pfu/mL. The OV 
PACR KO wells contained 13 and 18 plaques giving a viral titre of 7.75x102 pfu/mL.  
For the T5 samples from growth curve 1 the plaques present and viral output were 3 and 6 at 
10-5 dilution leading to 2.25x106 pfu/mL for OV 893, for Restore 17 and 13 plaques at 10-5 
dilution giving 7.50x106 pfu/mL. There were 18 and 19 plaques in the wells for the 10-4 dilution 
giving a viral output of 9.25x105 pfu/mL for the OV PACR KO. 
 
For LT growth curve 2, T0 plaque samples were counted from the 10-1 dilution wells. OV 
893 had 8 and 6 plaques in these 2 wells giving a viral titre of 3.50x101 pfu/mL. Restore had 
18 and 23 plaques in the wells giving a viral titre of 1.30x102 pfu/mL. OV PACR KO had 21 
and 20 plaques giving a viral titre of 1.03x102 pfu/mL. The T5 samples for OV 893 gave 26 
and 24 plaques in the 10-5 dilution wells giving a viral output of 1.25x107 pfu/mL. Restore 
had 24 and 29 plaques in the 10-5 dilution wells giving a viral output of 1.33x107 pfu/mL. The 
OV PACR KO wells contained 18 and 23 plaques at 10-4 giving 1.03x106 pfu/mL for the 
viral output. 
  
Figure 4A shows the result of averaging the two growth experiments. It shows that the average 
output titres for OV 893 and Restore are 7.38x106 and 1.04x107 pfu/mL, respectively. In 
contrast, the OV PACR KO average viral output was 9.75x105 pfu/mL. The difference in output 
titres between OV 893 and OV PACR KO is statistically significant with P < 0.05. An unpaired, 
two-tailed T-test with a 95% confidence interval (CI) was performed. The lower output titre 
for OV PACR KO ORFV was seen despite the T0 titre being slightly higher than that of OV 
893, 9.00x102 compared to 3.88x102 pfu/mL. These results are constant with work carried out 




Figure 4B shows the fold increase in the viral output titre compared to the initial titre. These 
were calculated by taking the average of the 4 values for each time point and then dividing the 
T5 value by the T0 value. This lead to OV 893 showing a 33548-fold increase, Restore a 14683-
fold and OV PACR KO a 1278-fold increase between the initial and output titres. This result 
showed OV 893 was able to replicate and grow in LT cells 26 times better than OV PACR KO 
orf virus. Together these results confirmed previous observations from the laboratory that the 

























































L T  C e l ls  (M O I  0 .0 1 )























































L T  C e l ls  (M O I  0 .0 1 )

































Figure 3. Plaque titrations of multi-step growth curves in LT cells show that OV 893 
and Restore grow better than OV PACR KO. A shows the results from LT multi-step 
growth curve 1 and B the results of LT multi-step growth curve 2. At time of infection, 
approximately 8x105 cells were present in each well and a MOI of 0.01 used. Cells were 
harvested immediately after infection (T0) or after 5 days (T5). Cell suspensions were then 
used for the plaque titrations in LT cells with the results shown in this figure. Each bar 
shows the average of duplicate titrations with standard deviation indicated. 
 
Figure 4. Plaque titrations of multi-step growth curves in LT cells show that OV 893 
and Restore grow better than OV PACR KO. A shows the results from LT multi-step 
growth curve 1 and B the results of LT multi-step growth curve 2. At time of infection, 
approximately 8x105 cells were present in each well and a MOI of 0.01 used. Cells were 
harvested immediately after infection (T0) or after 5 days (T5). Cell suspensions were then 
used for the plaque titrations in LT cells with the results shown in this figure. Each bar 
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Figure 5. A) Combined plaque titrations from LT multi-step growth curve 1 and 2. B) 
Fold increase of virus output compared to viral titre at T0. A) The graph is an average 
of the 4 data points from each time point with standard deviation indicated. The difference 
between the T5 OV 893 and T5 KO values are statistically significant with P < 0.05. The 
asterisk denotes results that are statistically significant when compared to the OV 893. 
B) To obtain the fold increase of the viral titre of the output compared to the initial viral 
titre the average value for the T5 sample was divided by the average value for the T0 sample. 
 
 
Figure 6. A) Combined plaque titrations from LT multi-step growth curve 1 and 2. B) 
Fold increase of virus output compared to viral titre at T0. A) The graph is an average 
of the 4 data points from each time point with standard deviation indicated. The difference 
between the T5 OV 893 and T5 KO values are statistically significant with P < 0.05. The 
asterisk denotes results that are statistically significant when compared to the OV 893. 
B) To obtain the fold increase of the viral titre of the output compared to the initial viral 




3.2 Analysis of viral growth in HeLa cells 
 
To examine whether the differences in growth characteristics between OV 893 and OV PACR 
KO orf virus seen in LT cells also occurred in HeLa cells multistep growth curves were 
performed in HeLa cells. The procedures used to set up the 6 well plates of HeLa cells and 
conduct the infections were the same as those described above for LT cells. Output viral titres 
were determined by plaque titration on LT cells, as described above. The only differences being 
that the plaque titrations used dilution series of, 10-1, 10-2, 10-3 for T0 samples and 10-3, 10-4, 
10-5 for T5 samples for all 3 viruses. The lower dilutions compared to the LT experiment were 
based on unpublished data from the VRU that shows orf virus does not grow as well in HeLa 
as it does in LT cells.  
 
Figure 5 shows the results of three independent growth experiments performed in HeLa cells. 
In HeLa growth curve 1, plaques from the 10-1 wells were counted for all the T0 samples, OV 
893 had 15 and 17 plaques in the 2 wells leading to a viral titre of 8.00x102 pfu/mL. For the 
Restore sample there were 35 and 35 plaques counted giving a viral titre of 1.75x103 pfu/mL 
while OV PACR KO had 17 and 15 plaques for a viral titre of 8.00x102 pfu/mL. For the T5 
samples all the plaques were counted in the 10-3 dilution wells, 1 and 1 were counted for OV 
893 for the giving a pfu/mL of 5.00x103, Restore had 1 and 2 giving a pfu/mL of 7.50x103 
while OV PACR KO had 3 and 0 giving a viral titre of 1.50x104 pfu/mL. 
 
For the second growth curve of HeLa cells plaques from the 10-1 dilution wells were counted 
for the all viruses at T0. OV 893 had 7 and 6 present in the wells, this gave an initial viral titre 
of 3.25x102 pfu/mL. With a viral titre at T0 of 1.10x103 pfu/mL Restore virus had 19 and 25 
plaques in the wells, OV PACR KO had a viral titre of 4.25x102 pfu/mL from 8 and 9 plaques 
in the wells. For the T5 samples the plaques present and viral outputs for OV 893 were 2 and 
2 at 10-3 dilution giving 1.00x104 pfu/mL, 3 and 3 at 10-3 dilution giving 1.5x104 pfu/mL for 
Restore and for OV PACR KO 3 and 2 plaques at 10-3 dilution giving a viral output of 1.25x104 
pfu/mL. 
Due to the lower than expected plaque counts in the first two HeLa cell growth curves, the 





For the third HeLa growth curve the viral titres were calculated using the 10-1 dilutions for all 
virus samples. In the 2 wells OV 893 had 5 and 8 plaques present giving a viral titre of 3.25x102 
pfu/mL. Restore had 5 and 7 plaques in the wells giving a viral titre of 3.00x102 pfu/mL and 
OV PACR KO had 6 and 4 plaques and a viral titre of 2.50x102 pfu/mL. For the T5 samples 
the plaques present and viral outputs were 29 and 28 at 10-2 dilution giving 1.42x104 pfu/mL 
for OV 893, 22 and 15 plaques at 10-2 dilution giving 9.25x103 for Restore and 21 and 20 
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Figure 7. Plaque titrations of multi-step growth curves in HeLa cells show that there 
is no difference between viral titres of OV 893 and OV PACR KO. A, B and C show 
the results from plaque titrations of HeLa growth curves 1,2 and 3, respectively. At time of 
infection, approximately 8x105 cells were present in each well and a MOI of 0.01 used. 
Cells were harvested either immediately after infection (T0) or after 5 days (T5). Cell 
suspensions were then used for the plaque titrations in LT cells. Each bar shows the average 
of duplicate titrations with the standard deviation indicated. 
 
 
Figure 8. Plaque titrations of multi-step growth curves in HeLa cells show that there 
is no difference between viral titres of OV 893 and OV PACR KO. A, B and C show 
the results from plaque titrations of HeLa growth curves 1,2 and 3, respectively. At time of 
infection, approximately 8x105 cells were present in each well and a MOI of 0.01 used. 
Cells were harvested either immediately after infection (T0) or after 5 days (T5). Cell 
suspensions were then used for the plaque titrations in LT cells. Each bar shows the average 
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Figure 6A is the result of averaging the titres from the plaque titrations for the 3 HeLa growth 
curves. The average output titres for the 3 viruses were 9.75x103 for OV 893, 1.06x104 for 
Restore and 1.00x104 for OV PACR KO. After statistical analysis the difference in viral output 
between OV 893 and OV PACR KO was not statistically significant with P > 0.05 when an 
unpaired, two-tailed T-test with a 95% CI was performed. This result is in contrast to that seen 
in LT cells where a clear difference between the two viruses was observed. At T0 OV 893 had 
similar titres in both LT and HeLa cells but at T5 OV 893 had a 1600 times greater fold increase 
in LT cells than HeLa cells. 
 
Figure 6B shows the fold increase in viral titre from the initial titre to the output when the 3 
growth experiments were combined. Based on this graph there is no evidence of the reduced 
growth of the OV PACR KO virus seen in LT cells, with both the OV PACR KO and OV 893 
having a 20 fold increase in viral load between T0 and T5 compared to more than a 10000 fold 
increase for OV 893 seen in LT cells. The somewhat lower fold increase for Restore compared 
with both OV 893 and KO is probably a result of the higher than expected T0 titre for Restore 
in two of the growth curves. The results of these growth experiments would suggest that orf 
virus does not grow as well in HeLa cells as LT cells and that the growth inhibition of OV 
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Figure 9. A) Combined plaque titrations from HeLa cell multi-step growth curve 1, 2 
and 3. B) Fold increase of virus output compared to viral titre at T0. A) The graph is 
an average of the 6 data points from each time point with standard deviation indicated. 
The difference between the T5 OV 893 and T5 KO values are not statistically significant 
with P ˃ 0.05.  
B) To obtain the fold increase of the viral titre of the output compared to the initial viral 






Figure 10. A) Combined plaque titrations from HeLa cell multi-step growth curve 1, 
2 and 3. B) Fold increase of virus output compared to viral titre at T0. A) The graph is 
an average of the 6 data points from each time point with standard deviation indicated. 
The difference between the T5 OV 893 and T5 KO values are not statistically significant 
with P ˃ 0.05.  
B) To obtain the fold increase of the viral titre of the output compared to the initial viral 







3.3 Analysis of viral growth in HDF cells 
 
Not much was known about the growth characteristics of orf virus in HDF cells except for the 
fact that it is  able to replicate in them (Mercer,personal communication), and the growth of 
OV PACR KO orf virus had not been previously examined in these cells. The growth curves 
were performed in the same manner as those described for LT cells. The dilution series carried 
out for T0 were undiluted, 10-1 and 10-2 and for T5 10-3, 10-4 and 10-5. These low dilutions were 
selected after the failure of one experiment to produce any plaques using higher dilutions.  
 
Figure 7A shows the results of HDF growth curve 1. For T0 plaques were counted from the 10-
1 dilution well for all 3 viruses. OV 893 had 18 and 17 plaques present in the wells giving a 
viral titre of 8.75x102 pfu/mL, 20 and 13 plaques for Restore gave a viral titre of 8.25x102 
pfu/mL. OV PACR KO had 10 and 11 plaques, therefore a viral titre of 5.25x102 pfu/mL. For 
the T5 samples the plaques present and viral outputs were 11 and 10 at 10-3 dilution giving 
5.25x104 pfu/mL for OV 893, 5 and 5 plaques at 10-3 dilution giving 2.50x104 for Restore and 
33 and 37 plaques for OV PACR KO at 10-2 dilution for a viral output of 1.75x104 pfu/mL. 
 
Figure 7B shows the results for HDF growth curve 2. For T0 plaques were counted from the 
10-1 dilution well for all 3 viruses. OV 893 had 10 and 7 plaques present in the wells giving a 
viral titre of 4.25x102 pfu/mL, 5 and 5 plaques for Restore gave a viral titre of 2.5x102 pfu/mL 
and OV PACR KO had 10 and 9 plaques, therefore a viral titre of 4.75x102 pfu/mL. For the T5 
samples the plaques present and viral outputs were 4 and 5 at 10-3 dilution giving 2.25x104 
pfu/mL for OV 893, 3 and 3 plaques at 10-3 dilution giving 1.50x104 for Restore and 8 and 11 
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Figure 11. Plaque titrations of multi-step growth curves in HDF cells show difference 
in viral titres between OV 893 and OV PACR KO. A and B are showing the results from 
plaque titrations of HDF growth curves 1 and 2 respectively. At time of infection, 8x105 
cells were present in each well and a viral input of 0.01 pfu/cell used. Cell suspensions were 
harvested either immediately after infection (T0) or after 5 days (T5). Cell suspensions were 
then used for the plaque titrations with the results shown in this figure. Each bar shows the 





Figure 12. Plaque titrations of multi-step growth curves in HDF cells show difference 
in viral titres between OV 893 and OV PACR KO. A and B are showing the results from 
plaque titrations of HDF growth curves 1 and 2 respectively. At time of infection, 8x105 
cells were present in each well and a viral input of 0.01 pfu/cell used. Cell suspensions were 
harvested either immediately after infection (T0) or after 5 days (T5). Cell suspensions were 
then used for the plaque titrations with the results shown in this figure. Each bar shows the 






Figure 8A is the average of the titres for each time point from the plaque titrations of the HDF 
growth curves. The average of the output titres for each virus were 3.75x104 pfu/mL for OV 
893, 2.00x104 for Restore and 1.11x104 for OV PACR KO. The difference in the viral output 
titres between OV 893 and OV PACR KO was statistically significant with P < 0.05 for an 
unpaired, two-tailed T-test with a 95% CI. The results from this growth experiment differ to 
those of the LT and HeLa experiments in that the Restore virus had lower viral output titres at 
T5 compared to OV 893. This was not observed in either of the other two cell types.  The titre 
of the Restore virus although low is still higher than that of the OV PACR KO virus. The 
difference between the Restore and OV PACR KO viruses was not statistically significant. 
 
Figure 8B shows the fold increase in viral titre between the initial titre and output. OV 893 had 
a 58-fold increase in titre which was the greatest increase of the 3 viruses, Restore was the next 
largest with a 37-fold increase followed by the OV PACR KO with a 26-fold increase. The 
results of these experiments show that the impaired growth of OV PACR KO orf virus relative 
to OV 893 is also apparent in HDF cells but that the difference between the two viruses are not 
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Figure 13. A) Combined plaque titrations from HDF cell multi-step growth curve 1 
and 2. B) Fold increase of virus output compared to viral titre at T0. A) The graph is 
an average of the 4 data points from each time point with standard deviations indicated. The 
difference between the T5 OV 893 and T5 KO values is statistically significant with P ˂ 
0.05. The asterisks denotes results that are statistically significant when compared to OV 
893. 
B) To obtain the fold increase of viral titre of the output compared to the initial viral titre 





Figure 14. A) Combined plaque titrations from HDF cell multi-step growth curve 1 
and 2. B) Fold increase of virus output compared to viral titre at T0. A) The graph is 
an average of the 4 data points from each time point with standard deviations indicated. The 
difference between the T5 OV 893 and T5 KO values is statistically significant with P ˂ 
0.05. The asterisks denotes results that are statistically significant when compared to OV 
893. 
B) To obtain the fold increase of viral titre of the output compared to the initial viral titre 






3.4 Single step growth curves. 
 
Based on the results from the multi-step growth curves HDF cells were selected for use in 
ongoing experiments and single step growth curves were carried out in HDF cells. These 
growth curves were undertaken to give an untransfected baseline against which the growth 
curves carried out in APC11 knock down cells could be compared. The same virus strains were 
used except for OV 893 which was replaced with OV 890 due to a lack of OV 893 viral stock. 
OV 890 has been shown to have the same growth characteristics as both WT orf virus and OV 
893 in terms of plaque size and virus yield (Mercer, Personal Communication). The single step 
growth curves were set up the same way as the multi-step growth curves except for adding 
virus at a MOI of 5 instead of 0.01. Samples were harvested at 5, 12, 24 and 48 hours post 
infection.  
 
The viral titre of these samples were calculated by carrying out plaque titrations in LT cells. 
The dilutions used were 10-2, 10-3 and 10-4 for 5 and 12 hours post infection and 10-3, 10-4 and 
10-5 for 24 and 48 hours post infection for HDF single step-growth curve 1.  
At 5 hours post infection for OV 890, 6 and 5 plaques were counted from the duplicate wells 
at the 10-3 dilution, giving a viral titre of 2.75x104 pfu/mL. Restore had 25 and 10 plaques 
present in the 10-3 dilution wells giving a viral titre of 8.75x104 pfu/mL. OV PACR KO had 6 
and 6 plaques present in the 10-3 dilution wells giving a viral titre of 3x104 pfu/mL. 
At 12 hours post infection OV 890 had 7 and 7 plaques present in the 10-3 dilution wells giving 
a viral titre of 3.5x104. Restore had 20 and 18 plaques present in the 10-3 dilution wells giving 
a viral titre of 9.5x104 pfu/mL. OV PACR KO had 8 and 9 plaques present in the 10-3 dilution 
wells giving a viral titre of 4.25x104 pfu/mL. 
At 24 hours post infection OV 890 had 24 and 23 plaques present in the 10-3 dilution wells 
giving a viral titre of 1.175x105. Restore had 53 and 37 plaques present in the 10-3 dilution 
wells giving a viral titre of 2.25x105 pfu/mL. OV PACR KO had 12 and 14 plaques present in 
the 10-3 dilution wells giving a viral titre of 6.6x104 pfu/mL. 
At 48 hours post infection OV 890 had 11 and 12 plaques present in the 10- dilution wells 
giving a viral titre of 5.75x105. Restore had 30 and 23 plaques present in the 10-4 dilution wells 
giving a viral titre of 1.325x106 pfu/mL. OV PACR KO had 17 and 19 plaques present in the 




For HDF single-step growth curve 2 OV 890 and Restore used 10-3, 10-4 and 10-5 dilutions for 
the 5 and 12 hour time points while 10-2, 10-3 and 10-4 were used for OV PACR KO. OV 890 
and Restore used 10-4, 10-5 and 10-6 dilutions for the 24 and 48 hour time points while 10-3, 10-
4 and 10-5 dilutions were used for OV PACR KO. 
 
At 5 hours post infection for OV 890, 8 and 9 plaques were counted from the duplicate wells 
at the 10-3 dilution, giving a viral titre of 4.25x104 pfu/mL. Restore had 19 plaques present in 
both the 10-3 dilution wells giving a viral titre of 9.5x104 pfu/mL. OV PACR KO had 9 plaques 
present in both the 10-3 dilution wells giving a viral titre of 4.5x104 pfu/mL. 
At 12 hours post infection OV 890 had 5 and 4 plaques present in the 10-3 dilution wells giving 
a viral titre of 2.25x104. Restore had 18 and 13 plaques present in the 10-3 dilution wells giving 
a viral titre of 7.75x104 pfu/mL. OV PACR KO had 12 and 9 plaques present in the 10-3 dilution 
wells giving a viral titre of 5.25x104 pfu/mL. 
At 24 hours post infection OV 890 had 2 and 1 plaques present in the 10-4 dilution wells giving 
a viral titre of 7.5x104. Restore had 4 and 2 plaques present in the 10-4 dilution wells giving a 
viral titre of 1.5x105 pfu/mL. OV PACR KO had 2 plaques present in both the 10-3 dilution 
wells giving a viral titre of 1x104 pfu/mL. 
At 48 hours post infection OV 890 had 7 and 13 plaques present in the 10-4 dilution wells giving 
a viral titre of 5x105. Restore had 25 and 23 plaques present in the 10-4 dilution wells giving a 
viral titre of 1.2x106 pfu/mL. OV PACR KO had 25 and 29 plaques present in the 10-3 dilution 
wells giving a viral titre of 1.35x105 pfu/mL. 
 
Figure 9 shows the averages of both growth curves combined. It can be seen that there is a 
distinct difference between the WT and OV PACR KO virus strains. The results of these 
experiments were statistically significant. The difference in the viral output titres between OV 
890 and OV PACR KO at 48 hours post infection was statistically significant with P < 0.05 for 




















Figure 16. OV PACR KO orf virus shows lower growth than OV 890 in HDF single-
step growth curve. HDF cells were infected (MOI 5) with a WT orf virus (OV 890), OV 
PACR KO (KO) and a OV PACR Restore recombinant (Restore) and harvested at 5, 12, 
24, 48 hours post infection. Viral titres were determined by plaque titrations on LT cells. 
Data shown are the averages ± SD of duplicate titrations of 2 independent experiments. The 
difference in the viral output titres between OV 890 and OV PACR KO at 48 hours post 
infection was statistically significant with P < 0.05 . The asterisk denotes results that are 





Figure 17. Western blots show knockdown of APC11 after RNAi in HDF cells. Lanes 
2-4 (left to right) of A were HDF cells transfected using the indicated concentrations of a 
smartpool siRNA comprised of 4 siRNAs directed against APC11 for 72 hours and then 
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3.5 APC11 knockdown by RNAi. 
 
After failing to show meaningful knockdown of APC11 with the current siRNAs available in 
the lab (results not shown) a new smartpool siRNA (Dharmacon) containing 4 different siRNA 
sequences was purchased. The new siRNA was first tested to see what concentration was 
needed for effective APC11 knockdown. To do this a 6 well plate was seeded with HDF cells. 
The cells were then transfected with 10, 50 and 100 nM concentrations (final) of siRNA and a 
negative control siRNA and left for up to 72 hours before harvesting. The negative control 
siRNA is a non-targeting siRNA that is used to show that the transfection is having no adverse 
effect on the cells. Once harvested a western blot to detect APC11 was performed on the cell 
lysates. This western is shown in Figure 10A. A time course of APC11 knockdown consisting 
of 12, 24 ,48 and 72 hours post transfection at 10 nM concentration was also carried out. This 
western blot is shown in Figure 10B. From these westerns we were able to determine that a 
concentration of 10 nM of siRNA was sufficient to significantly knockdown APC11 in HDF 
cells. It can be seen also that APC11 levels were effectively knocked down at 48 hours post 
transfection.  
 
To ensure that APC11 levels remained supressed for the full course of the planned studies, a 
time course was set up with APC11 knockdown cells harvested at 24, 48, 72, 96 and 120 hours 
post transfection. This western blot is shown in Figure 10C. From this we were able to see that 
APC11 levels remained inhibited right out to the end of the planned single step growth curves 


































Figure 19. Western blots show knockdown of APC11 after RNAi in HDF cells. Lanes 
2-4 (left to right) of A were HDF cells transfected using the indicated concentrations of a 
smartpool siRNA comprised of 4 siRNAs directed against APC11 for 72 hours and then 
harvested. In B, lanes 2-5 were HDF cells transfected using 10 nM of siRNA and harvested 
at the indicated hours post transfection (hpt). In C lanes 2-6 were HDF cells transfected 
using 10 nM of siRNA and harvested at the indicated hours post transfection. Lane 1 in A, 
B and C is a non-targeting negative control siRNA. All cells were harvested and prepared 
for western blot as described in 2.4.2. The top image in each figure is an anti-actin western, 
the bottom an anti-APC11 western. The ladder used was SeeBlue Plus2 with sizes indicated. 




3.6 APC11 knockdown HDF single-step growth curves. 
 
HDF cells were seeded in 6 well plates and left overnight. The next morning the HDF cells 
were transfected with 10nM of APC11 targeting siRNA for 72 hours before infection with OV 
890, OV PACR Restore and OV PACR KO virus strains at a MOI of 5. 72 hours post 
transfection was chosen for infection to ensure complete KD had occurred. Samples were 
harvested at 5, 12, 24 and 48 hours post infection.  
The viral titre of these samples were calculated by carrying out plaque titrations in LT cells. 
The dilutions used were 10-2, 10-3 and 10-4 for 5, 12 and 24 hours post infection and 10-3, 10-4 
and 10-5 for 48 hours post infection for both APC11 knockdown HDF single step-growth 
curves. 
 
At 5 hours post infection for HDF APC11 knockdown single-step growth curve 1 OV 890 had 
12 and 12 plaques present in the 10-3 dilution wells giving a viral titre of 6x104. Restore had 20 
and 21 plaques present in the 10-3 dilution wells giving a viral titre of 1.025x105 pfu/mL. OV 
PACR KO had 10 and 7 plaques present in the 10-3 dilution wells giving a viral titre of 4.25x104 
pfu/mL. 
At 12 hours post infection OV 890 had 15 and 7 plaques present in the 10-3 dilution wells giving 
a viral titre of 5.5x104. Restore had 14 and 8 plaques present in the 10-3 dilution wells giving a 
viral titre of 5.5x104 pfu/mL. OV PACR KO had 11 and 12 plaques present in the 10-3 dilution 
wells giving a viral titre of 6x104 pfu/mL. 
At 24 hours post infection OV 890 had 13 and 16 plaques present in the 10-3 dilution wells 
giving a viral titre of 7.25x104. Restore had 24 and 18 plaques present in the 10-3 dilution wells 
giving a viral titre of 1.05x105 pfu/mL. OV PACR KO had 11 and 15 plaques present in the 
10-3 dilution wells giving a viral titre of 6.5x104 pfu/mL. 
At 48 hours post infection OV 890 had 8 and 9 plaques present in the 10-4 dilution wells giving 
a viral titre of 4.25x105. Restore had 14 and 7 plaques present in the 10-4 dilution wells giving 
a viral titre of 5.25x105 pfu/mL. OV PACR KO had 14 and 13 plaques present in the 10-3 
dilution wells giving a viral titre of 6.75x104 pfu/mL. 
 
At 5 hours post infection for HDF APC11 knockdown single-step growth curve 2, OV 890 had 
9 and 18 plaques present in the 10-3 dilution wells giving a viral titre of 6.75x104. Restore had 
20 and 29 plaques present in the 10-3 dilution wells giving a viral titre of 1.225x105 pfu/mL. 
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OV PACR KO had 16 and 9 plaques present in the 10-3 dilution wells giving a viral titre of 
6.25x104 pfu/mL. 
At 12 hours post infection OV 890 had 19 and 13 plaques present in the 10-3 dilution wells 
giving a viral titre of 8x104. Restore had 20 and 25 plaques present in the 10-3 dilution wells 
giving a viral titre of 1.125x105 pfu/mL. OV PACR KO had 13 and 5 plaques present in the 
10-3 dilution wells giving a viral titre of 4.5x104 pfu/mL. 
At 24 hours post infection OV 890 had 180 and 185 plaques present in the 10-2 dilution wells 
giving a viral titre of 9.125x104. Restore had 31 and 42 plaques present in the 10-3 dilution 
wells giving a viral titre of 1.825x105 pfu/mL. OV PACR KO had 13 and 17 plaques present 
in the 10-3 dilution wells giving a viral titre of 7.5x104 pfu/mL. 
At 48 hours post infection OV 890 had 10 and 10 plaques present in the 10-4 dilution wells 
giving a viral titre of 5x105. Restore had 15 and 16 plaques present in the 10-3 dilution wells 
giving a viral titre of 7.75x105 pfu/mL. OV PACR KO had 9 and 14 plaques present in the 10-
3 dilution wells giving a viral titre of 5.75x104 pfu/mL. 
 
Figure 11 is the graph of the average of both APC11 KD HDF single-step growth curves. From 
this graph we can see that OV PACR KO titres remained essentially unchanged throughout the 
time course of the experiments. In contrast, OV 890 and Restore both showed growth 
characteristics typical of orf virus. The difference in the viral output titres between OV 890 and 
OV PACR KO was statistically significant with P < 0.05. This experiment revealed no evidence 
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Figure 21. OV PACR KO orf virus shows lower growth than OV 890 in APC11 KD 
HDF single-step growth curve. HDF cells were transfected with 10 nM of anti APC11 
siRNA as described in 2.3.2. After 72 hours these transfected cells were infected (MOI 5) 
with a WT orf virus (OV 890), OV PACR KO (KO) and an OV PACR Restore recombinant 
(Restore) and harvested at 5, 12, 24, 48 hours post infection. Viral titres were determined 
by plaque titrations on LT cells. Data shown are the averages ± SD of duplicate titrations of 
2 independent experiments. The difference in the viral output titres between OV 890 and 
OV PACR KO at 48 hours post infection was statistically significant with P < 0.05. The 





Figure 22. OV PACR KO orf virus shows lower growth than OV 890 in APC11 KD 
HDF single-step growth curve. HDF cells were transfected with 10 nM of anti APC11 
siRNA as described in 2.3.2. After 72 hours these transfected cells were infected (MOI 5) 
with a WT orf virus (OV 890), OV PACR KO (KO) and an OV PACR Restore recombinant 
(Restore) and harvested at 5, 12, 24, 48 hours post infection. Viral titres were determined 
by plaque titrations on LT cells. Data shown are the averages ± SD of duplicate titrations of 
2 independent experiments. The difference in the viral output titres between OV 890 and 
OV PACR KO at 48 hours post infection was statistically significant with P < 0.05. The 













































3.7 Analysis of cell cycle progression. 
 
The APC11 knockdown single-step growth curve experiments did not give the results that were 
hypothesised. Therefore FACS analysis was undertaken to assess if the APC11 KD was having 
an effect on the cell cycle as hypothesised. For this experiment 6 well plates were seeded with 
HDF cells and the next day were transfected with either 10nM of anti-APC11 siRNA or 
negative control siRNA. One well of each treatment was harvested at 24, 48 and 72 hours post 
transfection. A positive control was created through treating one well with Nocodazole, which 
causes cell arrest in G2/M phase. An untreated sample was also harvested at 24 hours after 
seeding. Cells were harvested and processed as described in 2.1.5/6. The cells were stained 
with propidium iodide (PI) and cellular content was determined by fluorescence-activated cell 
sorting (FACS). Results from the FACS analysis can be seen in Figure 12. The untreated 
sample had 48.85 % of cells in G1 phase, 25.92 % in S phase and 25.23 % in G2/M phase. The 
Nocodazole sample had 10.07 % of cells in G1 phase, 5.92 % in S phase and 84.02 % in G2/M 
phase. The 24 hr APC11 KD sample had 44.61 % of cells in G1 phase, 25.79 % in S phase and 
29.59 % in G2/M phase. The 48 hr APC11 KD sample had 83.62 % of cells in G1 phase, 3.81 
% in S phase and 12.58 % in G2/M phase. The 72 hr APC11 KD sample had 85.51 % of cells 
in G1 phase, 2.07 % in S phase and 12.41 % in G2/M phase.  The 24 hr negative control sample 
had 40.48 % of cells in G1 phase, 31.33 % in S phase and 28.18 % in G2/M phase. The 48 hr 
negative control sample had 78.23 % of cells in G1 phase, 6.06 % in S phase and 15.71 % in 
G2/M phase. The 72 hr negative control sample had 88.24 % of cells in G1 phase, 1.67 % in S 
phase and 10.09 % in G2/M phase. 
From these data there is no evidence of the APC11 KD having the hypothesised effect on the 
cell cycle as there is no increase in the proportion of cells in S phase and G2/M phase. This is 
in comparison to the addition of PACR to cells which does cause an increase in the percentage 
of cells in S and G2/M phases (Mo, 2008). These data show that when the cells are infected at 
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Figure 24. A) FACs analysis of cell cycle progression shows no evidence of APC11 KD 
influencing the cell cycle. HDF cells in 1 were untreated and harvested 24 hours after 
seeding. HDF cells in 5 were treated with Nocodazole and harvested 24 hours after seeding. 
HDF cells in 2-4 were transfected with non-targeting negative control siRNA while HDF 
cells in 6-8 were transfected with anti-APC11 siRNA and harvested at the indicated time. 
Harvested cells were then prepared as described in 2.1.5/6 including staining with PI. DNA 
contents were determined using the BD LSRFortessa flow cytometer and BD FACSDiva 
software and analysed using the MODFIT software program. 5000 cells were counted per 
sample. 
B) is indicative of the dot plot and gating strategies used during FACS analysis. 
 
 
Figure 25. A) FACs analysis of cell cycle progression shows no evidence of APC11 KD 
influencing the cell cycle. HDF cells in 1 were untreated and harvested 24 hours after 
seeding. HDF cells in 5 were treated with Nocodazole and harvested 24 hours after seeding. 
HDF cells in 2-4 were transfected with non-targeting negative control siRNA while HDF 
cells in 6-8 were transfected with anti-APC11 siRNA and harvested at the indicated time. 
Harvested cells were then prepared as described in 2.1.5/6 including staining with PI. DNA 
contents were determined using the BD LSRFortessa flow cytometer and BD FACSDiva 
software and analysed using the MODFIT software program. 5000 cells were counted per 
sample. 




3.8 Thymidine kinase levels in APC11 knockdown HDF cells. 
 
As a further measure of the functional effects of the APC11 knockdown, TK levels in APC11 
knockdown HDF cells were measured by western blotting. This was undertaken because as 
APC11 levels drop in the cell the amount of TK present should increase as TK is one of the 
enzymes regulated by the APC. TK is ubiquitinated by the APC and subsequently degraded by 
the 26s proteasome. In addition, inactivation of APC is part of the G1/S phase transition during 
which TK expression levels rise. The TK western blot was carried out as described in 2.4.3. 
The western blot shown in Figure 13 is representative of duplicate blots undertaken. Analysis 
of the bands was undertaken using Image J software. For each lane the value for the TK band 
was divided by the value for the actin control band, this gives a value that can then be used to 
directly compare the intensity of the bands at different times. The values for band intensity can 
be seen in Table 3. It can be seen both blots follow a similar pattern. TK levels remained 
unchanged at 24 hours post transfection (hpt) but then increased at 48 and 72 hpt. TK levels 
then fall again at 96 and 120 hpt. These data show a clear indication of the induction of TK 
levels by APC11 knock down and that the induction is greatest at 48-72 hpt. It should be noted 
that the two TK western blots were conducted using aliquots from a single growth curve. It 
will be important to conduct replicate growth curves before the indicative data shown here can 











Figure 26. A) Western blot of TK levels in APC11 knockdown HDF cells. Lanes 1-6 
(left to right) were HDF cells transfected with a negative control siRNA, lanes 7-12 were 
HDF cells transfected with 10 nM of an anti-APC11 siRNA. Transfected cells were 
harvested at the indicated hpt and prepared as described in 2.4.2. The top image is an anti-
actin loading control, the bottom an anti-TK western. The ladder used was SeeBlue Plus2 
with sizes indicated. This image is representative of duplicate western blots. The Western 
blot shown above corresponds to the Western blot 1 values in Table 3. 
B) Graphical representation of TK western blot intensities. The values depicted are band 
intensities that have been normalised to Actin. This is achieved by dividing the value for the 
TK band by the value of the Actin control band. 
 
 
Figure 27. X-Gluc assay shows similar trend in viral growth as single-step growth 
curves in HDF cells. A doubling dilution was carried out on the HDF single step growth 
curve samples and X-Gluc added. The plate was read after a 30 minute incubation using a 
Biorad model 630 microplate reader at 570nM. Data shown are from the ¼ dilution. Each 
point is an average of a single sample from 2 separate experiments. The samples were the 
same as in Figure 9.Figure 28. Western blot shows increased TK levels in APC11 
knockdown HDF cells. Lanes 1-6 (left to right) were HDF cells transfected with a negative 
































HPT Western blot 1 Western blot 2 
 APC11 KD Neg control APC11 KD Neg control 
0 0.154 0.239 0.096 0.522 
24 0.129 0.228 0.080 0.383 
48 1.794 0.810 2.899 0.906 
72 1.022 0.229 3.080 0.637 
96 0.225 0.149 0.267 0.404 
120 0.229 0.245 0.322 0.333 
Table 3 shows the values for band intensity once they have been normalised to Actin which 
is achieved by dividing the value for the TK band by the value of the Actin control band. 
 
Table 3 shows the values for band intensity once they have been normalised to Actin which 
is achieved by dividing the value for the TK band by the value of the Actin control band. 
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3.9 X-Gluc assay. 
 
Orf virus plaques take 5 days to develop and consequently, plaque titrations require a lot of 
time and resources to carry out. Therefore, a method of comparing the amount of virus present 
that is quicker would be advantageous. Both the OV 890 and OV PACR KO strains contain 
the β-glucuronidase reporter gene allowing for their detection via staining with X-Gluc (5-
Bromo-4-Chloro-3-Indoyl β-D-Glucuronide cyclohexylammonium) a substrate of β-
glucuronidase. Thus an assay using X-Gluc might be a viable alternative to plaque titration. 
The OV PACR Restore virus could not be used in this experiment as it carries a β- galactosidase 
reporter gene which is detected with X-Gal but not X-Gluc. The assay was set up as described 
in 2.2.3. Before the assay could be used for comparing OV 890 and OV PACR KO it first had 
to be optimised. Through various trials it was established that the appropriate setup was 100µL 
of sample diluted via a doubling dilution in DMEM with the addition of 1 µL of X-Gluc per 
well of a 96 well plate. The plates were read after a 30-minute incubation at 37°C in the dark. 
The same samples that were used for the plaque titrations described in section 3.4 (Figure 9) 
were used for the assay. Figure 14 shows the average of two X-Gluc assays performed on the 
2 different HDF single step growth curves. The OV 890 strain shows a time dependant increase 
in β-glucuronidase activity. By 48 hpi the level of activity was substantially greater than that 
seen with OV PACR KO infection, which showed only a modest increase in β-glucuronidase 
activity. One difference observed with the X-Gluc assay was evidence of increase activity at 
24 hpi. This is likely to reflect the fact that the β-glucuronidase assay measures viral gene 
expression which will be at significant levels before substantial levels of plaque forming virus 
is produced. 
 
The X-Gluc assay was also performed on the APC11 knockdown HDF single-step growth 
samples previously described in section 3.6 (Figure 11). The OV 890 strain shows a modest 
time dependant increase in β-glucuronidase activity, with the difference between the two strains 
not being pronounced until 48 hpi. The difference between the two virus strains is less than is 
seen when output was measured by plaque titration. This may be due to the X-Gluc assay not 
requiring full viral replication. This means that if the OV PACR KO virus was able to undergo 
viral gene transcription but was inhibited from forming mature virus in the APC11 knockdown 
cells it would still be picked up by the X-Gluc assay but not by plaque titration. This could 
account for the differing results between the plaque titrations and X-Gluc assay, but further 
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Figure 29. X-Gluc assay shows similar trend in viral growth as single-step growth 
curves in HDF cells. A doubling dilution was carried out on the HDF single step growth 
curve samples and X-Gluc added. The plate was read after a 30 minute incubation using a 
Biorad model 630 microplate reader at 570nM. Data shown are from the ¼ dilution. Each 
point is an average of a single sample from 2 separate experiments. The samples were the 
same as in Figure 9.  
 
 
Figure 30. X-Gluc assay shows similar trend in viral growth as single-step growth 
curves in HDF cells. A doubling dilution was carried out on the HDF single step growth 
curve samples and X-Gluc added. The plate was read after a 30 minute incubation using a 
Biorad model 630 microplate reader at 570nM. Data shown are from the ¼ dilution. Each 
point is an average of a single sample from 2 separate experiments. The samples were the 






   
  
Figure 31. X-Gluc assays show a narrowing of the difference in viral growth between 
OV 890 and OV PACR KO in APC11 KD cells. A doubling dilution was carried out on 
the single step growth curve samples and X-Gluc was added. The plate was read after a 30 
minute incubation using a Biorad model 630 microplate reader at 570nM. Data shown are 
from the ¼ dilution. Each point is an average of a single sample from 2 separate 
experiments. The samples tested were the same as those in Figure 11. 
 
Figure 32. X-Gluc assays show a narrowing of the difference in viral growth between 
OV 890 and OV PACR KO in APC11 KD cells. A doubling dilution was carried out on 
the single step growth curve samples and X-Gluc was added. The plate was read after a 30 
minute incubation using a Biorad model 630 microplate reader at 570nM. Data shown are 
from the ¼ dilution. Each point is an average of a single sample from 2 separate 
experiments. The samples tested were the same as those in Figure 11. 
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Chapter Four: Discussion 
 
The current model for PACR’s involvement in orf virus replication is that PACR inhibits the 
APC in host cells by replacing the APC11 subunit and binding in its place to APC2. The lack 
of ubiquitin ligase activity exhibited by PACR then causes a dysregulation in the cell cycle 
inducing the cell to enter a pseudo-S phase (Mo et al., 2009). This pseudo-S phase state leads 
to an increase in the host cell DNA synthesis pathways which are important as orf virus 
predominantly infects quiescent differentiated cells in which DNA metabolism enzymes are 
likely to be at low levels (Jenkinson et al., 1990). These enzymes can then be hijacked by orf 
virus for use in viral genome replication. PACR may be particularly important for 
parapoxviruses which lack many of the nucleotide metabolism genes commonly seen in other 
poxviruses. Linked to this model are observations that have been made in this lab that OV 
PACR KO orf virus shows reduced growth characteristics compared to those of the WT virus, 
due to the OV PACR KO virus being unable to induce the pseudo-S phase state. This leads to 
the formation of the main aim of my thesis which was to see if the model of PACR’s role in 
orf virus replication could be experimentally validated. Secondary aims that fell under this aim 
were firstly deciding which cell line was appropriate for growth experiments and secondly to 
see if it was possible to develop an X-Gluc assay that could be used to replace plaque titrations 
to compare viral growth between samples.  
 
In order to complete the main aim of my thesis RNAi was used to knock down the amount of 
APC11 present in HDF cells. This system is much more efficient than creating HDF cells that 
have had the APC11 gene entirely removed as it is difficult to achieve this and growing these 
cells to sufficient quantities for experimental use would also be extremely difficult if not 
impossible. By knocking down the amount of APC11 present in the cells it was thought that 
the WT and OV PACR KO orf viruses would have similar growth characteristics. Encoding 
PACR should confer no replicative advantage to the WT in APC11 KD cells.  
 
4.1 Role of PACR in orf virus growth in different cell types 
 
When orf virus multi-step growth curves were undertaken in LT cells the resulting plaque 
titrations agreed with the previous work that had shown that there is a distinct impairment in 
the growth characteristics of OV PACR KO orf virus compared with WT orf virus (Mo et al., 
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2009). Despite LT cells clearly showing that PACR plays a crucial role in orf virus growth they 
were not chosen for use in ongoing experiments, because there are very limited experimental 
reagents available for ovine cells and currently no commercially available anti ovine APC11 
siRNAs. Consequently 2 human cell lines were tested for suitability for the growth 
experiments; HeLa cells and HDF cells, with LT cell growth curves used as a benchmark. 
 
HeLa cells in contrast to LT cells did not show the difference in growth characteristics between 
the WT and OV PACR KO orf viruses with the later having a higher average viral titre. An 
explanation for this difference could be due to the fact that HeLa cells are human cervical 
cancer cells. As they are a cancer cell they express many proteins that have effects on the cell 
cycle such as the HPV protein E7. E7 is able to interact with tumour supressing RB protein 
(RBp) which has a role in controlling the progression of the cell cycle by inhibition of 
transcription factor E2F (Giacinti and Giordano, 0000). The interaction of E7 and RBp leads 
to a decrease in the inhibition of E2F causing the cell to enter into S phase and causing 
uncontrolled replication. As this is a similar effect to that seen with the addition of PACR it 
could be a contributing factor towards why we were unable to observe the difference in growth 
characteristics seen in LT. HeLa cells also express  HPV protein E6 which interacts with p53 
(Munagala et al., 2011), an important regulator of apoptosis. Despite the HeLa growth curve 
results being negative in the respect of being able to use them for ongoing experiments there 
are some positives to these observations. A positive outcome is that the oncogenic functions of 
some HeLa cell proteins lead to similar effects to PACR, meaning they are creating similar 
cellular conditions to those we are hoping to achieve with the knock down of APC11. The 
similar growth of WT and OV PACR KO orf virus in HeLa cells, therefore can be considered 
to be supportive of our model of PACR’s function. 
 
The growth characteristics of orf virus in HDF cells had not previously been extensively tested 
except to determine that orf virus is able to replicate in them. We hypothesised that the results 
would be similar to those of the LT experiments as both cells types are from natural hosts of 
orf virus and are primary fibroblast cells. The results of the multi-step growth curves did 
support our hypothesis with orf virus showing similar growth characteristics in HDF and LT 
cells, although at lower viral titres in HDF cells. The difference between the growth of WT and 
OV PACR KO orf virus strains in HDF cells was statistically significant. Due to this and the 
fact HDF cells are human cells and therefore have a larger pool of existing reagents to work 
with they were selected as the cell type to use in the ongoing experiments. 
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4.2 Viral growth in ovine and human cells 
 
There was a distinct difference in the growth of orf virus in human and ovine cells with the 
viral output titres being at least 100 times greater in ovine cells. This observation could be 
caused by orf virus being preferentially adapted to infect sheep and goats rather than humans. 
Although there was a difference in the final titres, the T0 titres were similar across the different 
cell types showing that infection of the cell is not influenced by whether the cell is human or 
ovine. Poxvirus proteins have been shown to exhibit species specificity, one such orf virus 
protein is GIF. GIF inhibits ovine IL-2 and granulocyte-macrophage colony-stimulating factor 
(Fleming et al., 2015), but this is not observed in the human versions. As there is a precedent 
for orf virus proteins to show species specificity there is the possibility that this could be 
occurring with PACR or other replication proteins albeit to a lesser degree. PACR, however 
has been shown to interact with the human APC (Mo et al., 2010), and as all mammalian APCs 
share extremely high sequence similarity (Fleming et al., 2015) it seems unlikely that PACR 
would show different activities between ovine and human APC. This does not rule out PACR 
binding with greater affinity to the ovine APC over human APC and thus having stronger 
effects. 
 
4.3 RNAi of APC11 
 
APC11 KD HDF cells were able to be created, despite the fact that APC genetic knock outs 
are lethal (Wirth et al., 2004). As APC11 is a critical part of the catalytic complex it begs the 
question of what is going on in the APC11 KD cells, as if the knock down is complete it should 
be lethal to the cell. Although the knock down wasn’t lethal it did affect the growth of the HDF 
cells. APC11 KD cells took up to 2 times longer to reach confluency in a 6 well plate when 
seeded at the same density as normal cells.  From the western blots we were able to see that the 
knock down was very effective with even concentrations as low as 10 nM showing what looks 
to be complete inhibition after 72 hours that extends out for at least 120 hours post transfection. 
The smartpool siRNA was much more effective than using multiple single siRNAs that the lab 
already had available. Experiments that were performed but not reported in this thesis showed 





If the APC11 KD wasn’t as effective as indicated in the westerns this could also explain why 
the knock down wasn’t lethal as small amounts of functioning APC might still be enough to 
stop the cell from undergoing apoptosis at the G2/M phase transition. To assess if this is the 
case qPCR could be undertaken to assess how much genetic material associated with APC11 
is present to see how much APC11 and therefore fully functioning APC is present. This would 
also back up the western blot results. 
 
4.4 Viral growth in APC11 KD HDF cells 
 
The results from the single step growth experiments in APC11 KD HDF cells were unexpected 
as it showed that contrary to our hypothesis the OV PACR KO virus grew worse than in normal 
HDF cells and that there was a greater difference between the WT and OV PACR KO strains. 
This result lead us to start entertaining the idea that the APC11 KD although effective at 
reducing the amount of APC11 present in the cells might not have been having the desired 
effect on the position of the cell in the cell cycle. Because the cell cycle is such a crucial 
function in the cell it is extremely tightly regulated and the cell may have been able to detect 
that the decrease in APC function occurred without the completion of other cell cycle 
checkpoints that would normally precede the progression of the cell into S phase. This 
dysregulation may then have inhibted the progression into S phase thus explaining the reduced 
growth of OV PACR KO orf virus as it would struggle to replicate effectively in cells in G1 
phase.  
 
For this to be the case PACR, although performing a similar function to the APC11 KD must 
have a subtler effect that does not induce a G1 phase block on cell cycle progression. In this 
scenario the WT and Restore orf viruses would still able to push the cell into the pseudo S 
phase allowing the viruses to replicate at similar levels to those seen in the normal HDF cells.  
 
Other viruses that target the APC such as human cytomegalovirus all inactivate subunits of the 
APC to stop the complex from working. Orf virus on the other hand encodes a structural 
homolog of APC11 which binds to the complex in place of APC11. Why would the virus go 
to this trouble unless by replacing the APC11 subunit it is able to do more than just stop the 




Not much is known about physical interactions with the APC at the G1/S phase transition, 
perhaps there is something that checks for a fully assembled APC (which APC plus PACR 
would resemble) before the cell can progress. Alternatively, APC plus PACR may have new 
activities that as yet have not been discovered. 
 
4.5 Analysis of cell cycle progression 
 
Following on from the results seen in the growth curves, attempts were made to see if the 
APC11 KD was in fact having functional effects on the cell. This lead to FACS analysis of the 
cell cycle status. If the knock down was causing similar effects to those seen during orf virus 
infection we would have expected to see a shift towards more cells in S or G2/M phase as is 
the case with the addition of PACR (Mo, 2008) and as seen in the nocodazole treated cells. 
FACS analysis using PI stain is unable to differentiate between G2 and M phase as they both 
contain a 4n amount of DNA, compared to 2n for cells in G1 phase. As seen in Figure 12 there 
was no increase in the proportion of cells in G2/M in the APC11 KD cells and there was in fact 
an increase in the proportion of cells in G1 phase which would add weight to the theory that the 
APC11 KD caused the cells to arrest in G1 phase rather than move through to S phase. This has 
also been observed in other studies looking at cell cycle progression after RNAi of APC11 (Shi 
and Huo, 2012a). Another potential reason for the increase in the proportion of cells in G1 
phase as time progresses is that APC inhibition can lead to metaphase-specific apoptosis of 
cells (Bellanger et al., 2005), which would account for the decrease in cells that were already 
at  G2/M  phase at the beginning of the experiment. 
 
As the levels of cells in G2/M phase at 24 hours were quite high then subsequently dropped 
down, any shift from G1 to G2/M could be masked. A way to help mitigate this issue would be 
to synchronise the cells into G1 before transfection as this should make it easier to detect any 
shift. Adding in additional time points including a 36 and 60 hour samples would give a clearer 
picture of what was occurring during the rise in APC mediated substrates. 
 
The APC is responsible for helping to mediate the separation of sister chromatids and 
disassembly of the mitotic spindle (Floyd et al., 2008; Nilsson et al., 2008). Dysregulation of 
this could lead to endoreduplication and the formation of polyploid cells. During FACS it was 
noticed that clusters of cells were seen that were to the right of the peak for G2/M phase 
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indicating that cells with DNA content of more than 4n were showing up. These peaks could 
be the product of these polyploid cells being formed due to incorrect chromatid separation. 
These cells are not part of the profile seen in Figure 12 as they are excluded from the sample 
during the gating step. To further assess the affect of orf virus infection in vivo FACS analysis 
of cell cycle progression could be carried out with synchronised cells so that any shift would 




4.6 Western blots of TK levels 
 
TK levels vary greatly during the cell cycle with little to none being present during G1 phase 
but with increasing amounts seen from S phase through to M phase (Sherley and Kelly, 1988). 
As TK is one of the substrates whose levels are controlled by the APC and is directly related 
to DNA replication it is a good candidate to assess its levels after APC11 KD. Western blots 
were performed on time courses of HDF cells after transfection with anti-APC11 siRNA. These 
western blots showed that the APC11 KD cells contained higher amounts of TK than the 
negative control cells. The increase in TK levels is only evident in the APC11 KD cells from 
48-72 hours and a small increase at 48 hours in the negative control. Infection of cells with WT 
orf virus leads to an increase in the amount of TK present while infection with a OV PACR 
KO orf virus shows no change in the levels of TK in the cells (Mercer). This result backs up 
our rational for the APC11 KD as it has been shown to have a similar effect on cells as the 
presence of PACR. 
 
A possible explanation for why we see an increase in TK without a shift into S phase is that in 
normal cells APC levels would only drop as the cell enters S phase (Vodermaier, 2004). This 
would then lead to increased TK levels. But in the APC11 KD cells the TK levels are increasing 
independently of cell cycle progression, perhaps solely through an inhibition of APC-directed 
degradation of TK in G1 phase. 
 
The TK westerns also suggest in the experiments conducted here, that the possible shift into 
pseudo-S phase and associated functional affects would occur around the 48 hour mark and be 
reducing by the time virus replication would be occurring in the cell as they are not infected 
until 72 hours after transfection. This raises the possibility that the APC11 KD had the desired 
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effect but due to the transfection-infection schedule used, we were unable to enhance the 
replication of OV PACR KO. To assess if this is the case growth curves would need to be 
carried out again but infecting the cells sooner after transfection so that they are replicating 
during the increased levels of TK and other enzymes. 
 
As we are seeing this drop in TK levels after 72 hours it raises the question of how the WT and 
Restore viruses are able to grow as well in the APC11 KD cells as they have in normal HDF 
cells since they should only have had access to the same levels of TK as the OV PACR KO orf 
virus in which case there should be no difference in viral yields. That is unless infection with 
these 2 viruses are able to cause a sustained surge in TK levels thus allowing for the similar 
viral yields to those seen in normal HDF cells. To assess this a TK western blot would need to 
be performed on WT and OV PACR KO orf virus infected APC11 KD cells. If this sustained 
rise in TK levels is seen in the WT infected cells it could lend support for the idea that maybe 
PACR has some other effect other than just replacing the APC11 subunit. It would also be 
important to repeat the experiment shown in Table 3, since these data show the results of a 
single growth curve. 
 
4.7 X-Gluc assay 
 
When the recombinant orf viruses used here were created, expression cassettes for X-Gluc or 
X-Gal were inserted into the genomes to aid in the identification of these viruses. This provided 
the opportunity to use these expression cassettes to assay the amount of virus present in a 
sample. This assay is not as accurate as plaque titration but rather than taking 5 days to complete 
the results can be obtained in a matter of hours. The results for the growth curve in normal 
HDF cells showed a similar trend to that seen in the multi-step growth curve with the major 
difference being that X-Gluc levels increased earlier than did the pfu count in the growth 
curves. This is most likely because mature virus is not required for the assay to produce colour, 
only viral gene expression whereas mature virus is required to see plaques during plaque 
titration. This assay clearly demonstrated reduced X-Gluc levels in PACR-KO infected cells. 
The assays that correspond to the APC11 KD growth curves showed differences between WT 
and PACR-KO, but not as great as seen in the growth curves, a likely reason for this is the 
aforementioned explanation about not requiring mature virus. The major limitation with this 
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assay is that unlike plaque titrations it cannot be used to quantify the amount of virus present 
and will never be as accurate but as a quick comparison it is useful.  
 
4.8 Have the aims been met? 
 
The preliminary aim of determining the best cell type to use for ongoing experiments was 
successful and the outcome of this was that HDF cells were selected for the later experiments. 
The main aim of my thesis was unable to be met as we were not able to show that the model 
for PACRs role in orf virus growth was either correct or incorrect. This was likely due to the 
time points that were tested not being able to give a clear picture of what was occurring during 
the rise in APC controlled substrates. The results obtained do look promising for supporting 
the model, but further experiments will be required. 
 
The aim of trying to find out if an X-Gluc assay could be used to replace plaque titrations was 
partially successful as the assay does work and is useful for providing a quick comparison of 
viral loads between samples but it is unable to quantify the amount of virus present, thus plaque 
titrations will still be needed to achieve that. 
 
4.9 Conclusions and future directions 
 
We were unable to induce a shift from G1 to G2/M following APC11 KD, raising the possibility 
that a more subtle approach might be needed to manipulate the cellular environment. One 
option is to create cell lines that carry the PACR gene in an inducible construct so that it would 
not impact on the cells in routine growth, but production of PACR could be switched on when 
virus infection was about to occur. There have been issues with inducible expression of PACR 
(Patel, 2016), so this approach would require more work to be undertaken before it could be 
used. 
 
A different course of action could be to increase levels of cell cycle regulatory proteins to make 
the cells enter S phase at the time the viruses are replicating. This would give the OV PACR 
KO and WT strains equal access to a more favourable replication environment. One such 
protein is early mitotic inhibitor-1 (EMI1) which inhibits the APC and allows for the 
accumulation of cell substrates during the G1/S phase transition (Reimann et al., 2001). 
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Experiments have shown that overexpression of EMI1 can override artificially induced G1 
block caused by the overexpression of cell cycle inhibitors such as Cdh1 (Hsu et al., 2002). 
 
Another potential approach would be to interfere with the ubiquitination process. This could 
be done by adding deubiquitylating enzymes to the cells in order to inhibit APC mediated 
degradation of host cell substrates (Amerik and Hochstrasser, 2004; Rape et al., 2006), this 
would allow accumulation of substrates such as RR and TK that would give the viruses an even 
playing field. Depleting free ubiquitin in the cell through the addition of the proteasome 
inhibitor MG132 could also be an option for stopping degradation of the APC substrates 
(Melikova et al., 2006). 
 
We have shown that HDF cells were the appropriate cells for these studies. Efficient knock 
down of APC11 was achieved in these cells and resulted in elevated levels of cellular TK but 
not in a rescue of OV PACR KO orf virus growth. APC11 knock down also did not have the 
hypothesised effects on the position of the cells in the cell cycle. Further experiments using a 
modified schedule will be required to complete the examination of the mechanism by which 










Acquaviva, C., Herzog, F., Kraft, C., and Pines, J. (2004). The anaphase promoting 
complex/cyclosome is recruited to centromeres by the spindle assembly checkpoint. Nature 
cell biology 6, 892. 
 
Amerik, A.Y., and Hochstrasser, M. (2004). Mechanism and function of deubiquitinating 
enzymes. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1695, 189-207. 
 
Baker, D.J., Dawlaty, M., Galardy, P., and Van Deursen, J. (2007). Mitotic regulation of the 
anaphase-promoting complex. Cellular and molecular life sciences 64, 589-600. 
 
Baulcombe, D. (1999). Viruses and gene silencing in plants. In 100 Years of Virology 
(Springer), pp. 189-201. 
 
Bellanger, S., Blachon, S., Mechali, F., Bonne-Andrea, C., and Thierry, F. (2005). High-risk 
but not low-risk HPV E2 proteins bind to the APC activators Cdh1 and Cdc20 and cause 
genomic instability. Cell cycle (Georgetown, Tex) 4, 1608-1615. 
 
Broyles, S.S. (2003). Vaccinia virus transcription. Journal of General Virology 84, 2293-
2303. 
 
Buller, R., and Palumbo, G.J. (1991). Poxvirus pathogenesis. Microbiological reviews 55, 80-
122. 
 
Chang, L., Zhang, Z., Yang, J., McLaughlin, S.H., and Barford, D. (2014). Molecular 
architecture and mechanism of the anaphase-promoting complex. Nature 513, 388-393. 
 
Delhon, G., Tulman, E.R., Afonso, C.L., Lu, Z., de la Concha-Bermejillo, A., Lehmkuhl, 
H.D., Piccone, M.E., Kutish, G.F., and Rock, D.L. (2004). Genomes of the parapoxviruses 
ORF virus and bovine papular stomatitis virus. Journal of virology 78, 168-177. 
 
Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E., and Mello, C.C. (1998). 
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. 
nature 391, 806. 
 
Fleming, S.B., McCaughan, C.A., Andrews, A.E., Nash, A.D., and Mercer, A.A. (1997). A 
homolog of interleukin-10 is encoded by the poxvirus orf virus. Journal of virology 71, 4857-
4861. 
 





Fleming, S.B., Wise, L.M., and Mercer, A.A. (2015). Molecular genetic analysis of orf virus: 
a poxvirus that has adapted to skin. Viruses 7, 1505-1539. 
 
Floyd, S., Pines, J., and Lindon, C. (2008). APC/CCdh1 targets aurora kinase to control 
reorganization of the mitotic spindle at anaphase. Current Biology 18, 1649-1658. 
 
Giacinti, C., and Giordano, A. (0000). RB and cell cycle progression. Oncogene 25, 5220-
5227. 
 
Gomez, C., and Esteban, M. (2001). Recombinant proteins produced by vaccinia virus 
vectors can be incorporated within the virion (IMV form) into different compartments. 
Archives of virology 146, 875-892. 
 
Groves, R.W., Wilson-Jones, E., and MacDonald, D.M. (1991). Human orf and milkers' 
nodule: A clinicopathologic study. Journal of the American Academy of Dermatology 25, 
706-711. 
 
Gubser, C., Hue, S., Kellam, P., and Smith, G.L. (2004). Poxvirus genomes: a phylogenetic 
analysis. The Journal of general virology 85, 105-117. 
 
Hagting, A., Den Elzen, N., Vodermaier, H.C., Waizenegger, I.C., Peters, J.-M., and Pines, J. 
(2002). Human securin proteolysis is controlled by the spindle checkpoint and reveals when 
the APC/C switches from activation by Cdc20 to Cdh1. The Journal of cell biology 157, 
1125-1137. 
 
Haig, D.M., and McInnes, C.J. (2002a). Immunity and counter-immunity during infection 
with the parapoxvirus orf virus. Virus research 88, 3-16. 
 
Haig, D.M., and McInnes, C.J. (2002b). Immunity and counter-immunity during infection 
with the parapoxvirus orf virus. Virus research 88, 3-16. 
 
Hall, M.C., Warren, E.N., and Borchers, C.H. (2004). Multi-kinase phosphorylation of the 
APC/C activator Cdh1 revealed by mass spectrometry. Cell cycle (Georgetown, Tex) 3, 
1278-1284. 
 
Hammond, S.M., Bernstein, E., Beach, D., and Hannon, G.J. (2000). An RNA-directed 
nuclease mediates post-transcriptional gene silencing in Drosophila cells. nature 404, 293. 
 
Hsiao, J.-C., Chung, C.-S., and Chang, W. (1999). Vaccinia virus envelope D8L protein binds 
to cell surface chondroitin sulfate and mediates the adsorption of intracellular mature virions 
to cells. Journal of virology 73, 8750-8761. 
 
Hsu, J.Y., Reimann, J.D., Sørensen, C.S., Lukas, J., and Jackson, P.K. (2002). E2F-dependent 
accumulation of hEmi1 regulates S phase entry by inhibiting APC Cdh1. Nature cell biology 
4, 358. 
 
Jenkinson, D.M., McEWAN, P.E., MOSS, V.A., and ELDER, H.Y. (1990). Location and 
spread of orf virus antigen in infected ovine skin. Veterinary Dermatology 1, 189-195. 
71 
 
Johnston, J., and McFadden, G. (2004). Technical knockout: understanding poxvirus 
pathogenesis by selectively deleting viral immunomodulatory genes. Cellular microbiology 6, 
695-705. 
 
Johnston, J.B., and McFadden, G. (2003). Poxvirus immunomodulatory strategies: current 
perspectives. Journal of virology 77, 6093-6100. 
 
Katoh, S., Tsunoda, Y., Murata, K., Minami, E., and Katoh, E. (2005). Active-site residues 
and amino acid specificity of the E2-binding RING-H2 finger domain. Journal of Biological 
Chemistry. 
 
Katsafanas, G.C., and Moss, B. (2007). Colocalization of transcription and translation within 
cytoplasmic poxvirus factories coordinates viral expression and subjugates host functions. 
Cell host & microbe 2, 221-228. 
 
Ku, C.-C., Zerboni, L., Ito, H., Graham, B.S., Wallace, M., and Arvin, A.M. (2004). 
Varicella-zoster virus transfer to skin by T cells and modulation of viral replication by 
epidermal cell interferon-α. Journal of Experimental Medicine 200, 917-925. 
 
Leverson, J.D., Joazeiro, C.A., Page, A.M., Huang, H.-k., Hieter, P., and Hunter, T. (2000). 
The APC11 RING-H2 finger mediates E2-dependent ubiquitination. Molecular biology of the 
cell 11, 2315-2325. 
 
Locker, J.K., Kuehn, A., Schleich, S., Rutter, G., Hohenberg, H., Wepf, R., and Griffiths, G. 
(2000). Entry of the two infectious forms of vaccinia virus at the plasma membane is 
signaling-dependent for the IMV but not the EEV. Molecular biology of the cell 11, 2497-
2511. 
 
McFadden, G. (2005). Poxvirus tropism. Nature reviews Microbiology 3, 201-213. 
 
McKeever, D., Jenkinson, D.M., Hutchison, G., and Reid, H. (1988). Studies of the 
pathogenesis of orf virus infection in sheep. Journal of comparative pathology 99, 317-328. 
 
Melikova, M.S., Kondratov, K.A., and Kornilova, E.S. (2006). Two different stages of 
epidermal growth factor (EGF) receptor endocytosis are sensitive to free ubiquitin depletion 
produced by proteasome inhibitor MG132. Cell biology international 30, 31-43. 
 
Mercer, A. Personal communication. 
 
Mercer, A.A., Ueda, N., Friederichs, S.M., Hofmann, K., Fraser, K.M., Bateman, T., and 
Fleming, S.B. (2006). Comparative analysis of genome sequences of three isolates of Orf 
virus reveals unexpected sequence variation. Virus research 116, 146-158. 
 
Mercer, J., and Helenius, A. (2008). Vaccinia virus uses macropinocytosis and apoptotic 
mimicry to enter host cells. Science 320, 531-535. 
 





Miller, S.C., Brown, S.J., and Tomoyasu, Y. (2008). Larval RNAi in Drosophila? 
Development genes and evolution 218, 505-510. 
 
Mo, M. (2008). Characterization of an orf virus RING-H2 protein, B5L: a mimic of cellular 
anaphase promoting complex subunit 11. In Department of Microbiology (Otago: University 
of Otago). 
 
Mo, M., Fleming, S.B., and Mercer, A.A. (2009). Cell cycle deregulation by a poxvirus 
partial mimic of anaphase-promoting complex subunit 11. Proceedings of the National 
Academy of Sciences 106, 19527-19532. 
 
Mo, M., Fleming, S.B., and Mercer, A.A. (2010). Orf virus cell cycle regulator, PACR, 
competes with subunit 11 of the anaphase promoting complex for incorporation into the 
complex. The Journal of general virology 91, 3010-3015. 
 
Mo, M., Shahar, S., Fleming, S.B., and Mercer, A.A. (2012). How viruses affect the cell 
cycle through manipulation of the APC/C. Trends in microbiology 20, 440-448. 
 
Mohamed, M.R., and McFadden, G. (2009). NFkB inhibitors: strategies from poxviruses. 
Cell cycle (Georgetown, Tex) 8, 3125-3132. 
 
Moss, B. (2001). Fields virology. Chapter 74, 2905-2945. 
 
Moss, B. (2013). Poxvirus DNA replication. Cold Spring Harbor perspectives in biology 5. 
 
Munagala, R., Kausar, H., Munjal, C., and Gupta, R.C. (2011). Withaferin A induces p53-
dependent apoptosis by repression of HPV oncogenes and upregulation of tumor suppressor 
proteins in human cervical cancer cells. Carcinogenesis 32, 1697-1705. 
 
Nilsson, J., Yekezare, M., Minshull, J., and Pines, J. (2008). The APC/C maintains the 
spindle assembly checkpoint by targeting Cdc20 for destruction. Nature cell biology 10, 
1411. 
 
Patel, P. (2016). Examining inducible expression of the poxvirus anaphase-promoting 
comples regulator (PACR). In Department of Microbiology (Otago: University of Otago). 
 
Peters, J.-M. (2006). The anaphase promoting complex/cyclosome: a machine designed to 
destroy. Nature reviews Molecular cell biology 7, 644. 
 
Rape, M., Reddy, S.K., and Kirschner, M.W. (2006). The Processivity of Multiubiquitination 
by the APC Determines the Order of Substrate Degradation. Cell 124, 89-103. 
 
Reimann, J.D., Freed, E., Hsu, J.Y., Kramer, E.R., Peters, J.-M., and Jackson, P.K. (2001). 
Emi1 is a mitotic regulator that interacts with Cdc20 and inhibits the anaphase promoting 
complex. Cell 105, 645-655. 
 
Scheffner, M., Nuber, U., and Huibregtse, J.M. (1995). Protein ubiquitination involving an 




Schmidt, F.I., Bleck, C.K., and Mercer, J. (2012). Poxvirus host cell entry. Current opinion in 
virology 2, 20-27. 
 
Schwartz, P., MD, Alan L, and Ciechanover, M., PhD, Aaron (1999). The ubiquitin-
proteasome pathway and pathogenesis of human diseases. Annual review of medicine 50, 57-
74. 
 
Seet, B.T., Johnston, J., Brunetti, C.R., Barrett, J.W., Everett, H., Cameron, C., Sypula, J., 
Nazarian, S.H., Lucas, A., and McFadden, G. (2003a). Poxviruses and immune evasion. 
Annual review of immunology 21, 377-423. 
 
Seet, B.T., McCaughan, C.A., Handel, T.M., Mercer, A., Brunetti, C., McFadden, G., and 
Fleming, S.B. (2003b). Analysis of an orf virus chemokine-binding protein: Shifting ligand 
specificities among a family of poxvirus viroceptors. Proceedings of the National Academy 
of Sciences 100, 15137-15142. 
 
Sherley, J., and Kelly, T.J. (1988). Regulation of human thymidine kinase during the cell 
cycle. Journal of Biological Chemistry 263, 8350-8358. 
 
Shi, Y., and Huo, K. (2012a). Knockdown expression of Apc11 leads to cell-cycle 
distribution reduction in G2/M phase. Genetics and molecular research: GMR 11, 2814-2822. 
 
Shi, Y.J., and Huo, K.K. (2012b). Knockdown expression of Apc11 leads to cell-cycle 
distribution reduction in G2/M phase. Genetics and molecular research : GMR 11, 2814-
2822. 
 
Skaar, J.R., and Pagano, M. (2009). Control of cell growth by the SCF and APC/C ubiquitin 
ligases. Current opinion in cell biology 21, 816-824. 
 
Smith, G.L., and Law, M. (2004). The exit of vaccinia virus from infected cells. Virus 
research 106, 189-197. 
 
Smith, G.L., and McFadden, G. (2002). Smallpox: anything to declare? Nature reviews 
Immunology 2, 521-527. 
 
Spehner, D., De Carlo, S., Drillien, R., Weiland, F., Mildner, K., Hanau, D., and Rziha, H.-J. 
(2004). Appearance of the bona fide spiral tubule of ORF virus is dependent on an intact 10-
kilodalton viral protein. Journal of virology 78, 8085-8093. 
 
Sudakin, V., Ganoth, D., Dahan, A., Heller, H., Hershko, J., Luca, F., Ruderman, J., and 
Hershko, A. (1995). The cyclosome, a large complex containing cyclin-selective ubiquitin 
ligase activity, targets cyclins for destruction at the end of mitosis. Molecular biology of the 
cell 6, 185-197. 
 
Tan, J.L., Ueda, N., Mercer, A.A., and Fleming, S.B. (2009). Investigation of orf virus 
structure and morphogenesis using recombinants expressing FLAG-tagged envelope 
structural proteins: evidence for wrapped virus particles and egress from infected cells. The 




Thornton, B.R., and Toczyski, D.P. (2003). Securin and B-cyclin/CDK are the only essential 
targets of the APC. Nature cell biology 5, 1090. 
 
Tran, K., Mahr, J.A., Choi, J., Teodoro, J.G., Green, M.R., and Spector, D.H. (2008). 
Accumulation of substrates of the anaphase-promoting complex (APC) during human 
cytomegalovirus infection is associated with the phosphorylation of Cdh1 and the 
dissociation and relocalization of APC subunits. Journal of virology 82, 529-537. 
 
Upton, C., Slack, S., Hunter, A.L., Ehlers, A., and Roper, R.L. (2003). Poxvirus orthologous 
clusters: toward defining the minimum essential poxvirus genome. Journal of virology 77, 
7590-7600. 
 
Vodermaier, H.C. (2004). APC/C and SCF: controlling each other and the cell cycle. Current 
Biology 14, R787-R796. 
 
Westphal, D., Ledgerwood, E.C., Hibma, M.H., Fleming, S.B., Whelan, E.M., and Mercer, 
A.A. (2007). A novel Bcl-2-like inhibitor of apoptosis is encoded by the parapoxvirus ORF 
virus. Journal of virology 81, 7178-7188. 
 
Wirth, K.G., Ricci, R., Giménez-Abián, J.F., Taghybeeglu, S., Kudo, N.R., Jochum, W., 
Vasseur-Cognet, M., and Nasmyth, K. (2004). Loss of the anaphase-promoting complex in 
quiescent cells causes unscheduled hepatocyte proliferation. Genes & development 18, 88-98. 
 
Wise, L., McCaughan, C., Tan, C.K., Mercer, A.A., and Fleming, S.B. (2007). Orf virus 
interleukin-10 inhibits cytokine synthesis in activated human THP-1 monocytes, but only 
partially impairs their proliferation. Journal of general virology 88, 1677-1682. 
 
Wise, L.M., Inder, M.K., Real, N.C., Stuart, G.S., Fleming, S.B., and Mercer, A.A. (2012). 
The vascular endothelial growth factor (VEGF)-E encoded by orf virus regulates keratinocyte 
proliferation and migration and promotes epidermal regeneration. Cellular microbiology 14, 
1376-1390. 
 
Wise, L.M., Veikkola, T., Mercer, A.A., Savory, L.J., Fleming, S.B., Caesar, C., Vitali, A., 
Makinen, T., Alitalo, K., and Stacker, S.A. (1999). Vascular endothelial growth factor 
(VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1. Proceedings of 
the National Academy of Sciences of the United States of America 96, 3071-3076. 
 
Wittek, R., Kuenzle, C.C., and Wyler, R. (1979). High C+ G content in parapoxvirus DNA. 
Journal of General Virology 43, 231-234. 
 
Zeng, L.P., Gao, Y.T., Ge, X.Y., Zhang, Q., Peng, C., Yang, X.L., Tan, B., Chen, J., Chmura, 
A.A., Daszak, P., et al. (2016). Bat Severe Acute Respiratory Syndrome-Like Coronavirus 
WIV1 Encodes an Extra Accessory Protein, ORFX, Involved in Modulation of the Host 




























Supplementary Figure 1. Full Western Blot of cropped images 10A and 10B. Lanes 
1-4 correspond to Figure 10A and lanes 5- 9 correspond to 10B. Lane 10 is the SeeBlue 
Plus2 ladder. 
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